thiotepa profile

Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed). [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	5453
CHEMBL ID	671
CHEBI ID	9570
SCHEMBL ID	4760
MeSH ID	M0021343

Synonym
BIDD:GT0127
AB00052346-06
triethylenethiophosphoramide
stepa
tio tef
thiotriethylenephosphoramide
thiophosphoramide,n',n''-tri-1,2-ethanediyl-
thio-tep
phosphorothioic triamide,n',n''-triethylene
n,n''-triethylenephosphorothioic triamide
aziridine,1',1''-phosphinothioylidynetris-
thio-tepa s
triaziridinylphosphine sulfide
tifosyl
wln: t3ntj aps&- at3ntj&- at3ntj
triethylenethiophosphorotriamide
tris(1-aziridinyl)phosphine sulfide
tio-tef
oncothio-tepa
mls003389372 ,
n,n''-triethylenethiophosphamide
tespamine
tiofosfamid
sk 6882
nci-c01649
thio-tepa
triethylene thiophosphoramide
tri(ethyleneimino)thiophosphoramide
thiophosphamide
oncotiotepa
tiofozil
thiophosphoramide,n',n'' -triethylene-
phosphorothioic triamide,n',n''-tri-1,2-ethanediyl-
cbc 806495
phosphorothioic acid triethylenetriamide
tiofosyl
n,n''-triethylenethiophosphoramide
thiotef
tespa
nsc-6396
n,n''-tri-1,2-ethanediylphosphorothioic triamide
phosphine sulfide, tris(1-aziridinyl)-
n,n''-tri-1,2-ethanediylthiophosphoramide
thioplex (tn) (immunex)
tespamin
girostan
1,1''-phosphinothioylidynetrisaziridine
thiofozil
tris(ethylenimino)thiophosphate
oncotepa
nsc6396
DIVK1C_000817
KBIO1_000817
NCI60_013117
1,1',1''-phosphorothioyltriaziridine
SPECTRUM_001689
SPECTRUM5_001641
IDI1_000817
ledertepa
tris(aziridin-1-yl)-thioxo-$l^{5}-phosphane
aziridine, 1,1',1''-phosphinothioylidynetris-
thioplex
n,n',n''-tri-1,2-ethanediylphosphorothioic triamide
ai3-24916
1,1',1''-phosphinothioylidynetrisaziridine
phosphorothioic triamide, n,n',n''-tri-1,2-ethanediyl-
tris(aziridinyl)phosphine sulfide
hsdb 3258
n,n',n''-triethylenethiophosphoramide
einecs 200-135-7
tri-1-aziridinylphosphine sulfide
tris(1-aziridinyl)phosphine sulphide
n,n',n''-tri-1,2-ethanediylthiophosphoramide
n,n',n''-triethylenephosphorothioic triamide
thiotepum [inn-latin]
thiophosphamidum
nsc 6396
brn 0145978
ccris 586
tiotepa [inn-spanish]
n,n',n''-triethylenethiophosphamide
thiophosphoramide, n,n',n''-tri-1,2-ethanediyl-
n,n',n''-triethylenethiophosphortriamide
wr-45312
52-24-4
C07641
thiotepa
thio-tepa, 98%, solid
DB04572
D00583
thiotepa (jan/usp/inn)
thioplex (tn)
tepadina (tn)
rethio (tn)
NCGC00095042-01
NCGC00095042-03
NCGC00095042-02
NCGC00095042-04
KBIO3_002688
KBIOSS_002169
KBIOGR_000815
KBIO2_004737
KBIO2_007305
KBIO2_002169
SPECTRUM3_001594
SPECTRUM2_001557
SPBIO_001434
NINDS_000817
SPECTRUM4_000208
SPECTRUM1503324
BSPBIO_003188
tris(aziridinyl)-phosphine sulfide (thio-tepa)
NCGC00095042-05
MLS001333084
MLS001333083 ,
smr000058542
MLS002207150
HMS2093E05
CHEMBL671
chebi:9570 ,
HMS502I19
HMS1922A14
AKOS005267118
NCGC00095042-06
NCGC00095042-07
wr 45312
905z5w3gkh ,
tiotepa
ai 3-24916
phosphorothioic triamide, n,n',n''-triethylene-
thiophosphoramide, n,n',n''-triethylene-
thiotepum
thiotepa [usp:inn:ban:jan]
4-20-00-00052 (beilstein handbook reference)
unii-905z5w3gkh
aziridine,1,1',1''-phosphinothioylidynetris-
dtxcid201339
tox21_400065
cas-52-24-4
dtxsid0021339 ,
A828998
pharmakon1600-01503324
nsc758455
nsc-758455
tox21_111399
tri(aziridin-1-yl)phosphine sulfide
HMS2232P17
CCG-39776
bdbm50418086
FT-0600281
GC10080
NCGC00095042-08
thiotepa [iarc]
tepadina
phosphorothioic tri(ethyleneamide)
thiotepa [usp-rs]
thiotepa [hsdb]
thiotepa [jan]
1,1',1''-phosphinothioylidynetris(aziridine)
thiotepa [inn]
thiotepa [vandf]
thiotepa [mi]
thiotepa [orange book]
thiotepa [usp monograph]
thiotepa [who-dd]
thiotepa [mart.]
thiotepa [ema epar]
S1775
HMS3372D10
CS-3119
HY-17574
tris(aziridin-1-yl)-sulfanylidenephosphorane
gtpl7622
MLS006009972
SCHEMBL4760
NCGC00095042-09
Q-201826
1-[di(1-aziridinyl)phosphorothioyl]aziridine #
thiophosphoramide, n,n',n'' -triethylene-
phosphorothioic triamide, n,n',n''-triethylene
AB00052346_07
tri(1-aziridinyl)phosphine sulfide
mfcd00145452
tris(aziridin-1-yl)-$l^{5}-phosphanethione
SR-05000001855-5
sr-05000001855
thiotepa, united states pharmacopeia (usp) reference standard
SR-05000001855-1
n,n',n'''-triethylenethiophosphhoramide
tris(aziridin-1-yl)-lambda5-phosphanethione
EN300-120883
SBI-0051814.P002
BCP04110
Q416507
Z1201619320
1631739-26-8
AS-16885
BRD-K09631521-001-05-7
tris(aziridin-1-yl)-sulfanylidene-lambda5-phosphane
AMY33389
thiotepa (thioplex)
tris(aziridin-1-yl)-\|e?-phosphanethione

Excerpt	Reference	Relevance
"Thiotepa is a common alkylating agent known to precipitate cutaneous reactions consistent with toxic erythema of chemotherapy, including erythema and hyperpigmentation. "	( Thiotepa hyperpigmentation preceding epidermal necrosis: malignant intertrigo misdiagnosed as Stevens-Johnson syndrome-toxic epidermal necrolysis overlap. Choate, EA; Sarantopoulos, GP; Truong, AK; Worswick, SD, 2020)	3.44
"Thiotepa is an alkylating compound with an antineoplastic and myeloablative activity and can mimic the effect of radiation. "	( Thiotepa-based versus total body irradiation-based myeloablative conditioning prior to allogeneic stem cell transplantation for acute myeloid leukaemia in first complete remission: a retrospective analysis from the Acute Leukemia Working Party of the Euro Arcese, W; Bacigalupo, A; Beelen, D; Cornelissen, J; de Rosa, G; Eder, S; Kuball, J; Labopin, M; Majolino, I; Mohty, M; Nagler, A; Or, R; Schaap, NP; Veelken, H; Volin, L, 2016)	3.32
"ThioTEPA is a chemotherapeutic agent used in the treatment of cancers, and more recently has been proposed as a component of high-dose therapy for young patients with recurrent malignant brain tumors. "	( The chemotherapy agent, thioTEPA, yields long-term impairment of hippocampal cell proliferation and memory deficits but not depression-related behaviors in mice. Gulinello, ME; Mondie, CM; Vandergrift, KA; Weber, ET; Wilson, CL, 2010)	2.11
"Thiotepa (TTP) is an alkylating agent that has been used mainly in breast and ovarian cancer with 20-50% response rates."	( The role of thiotepa in autologous bone marrow transplantation for acute leukemia. Finlander, R; Nagler, A; Naparstek, E; Or, R; Slavin, S; Varadi, G, 1998)	1.4
"Thiotepa is a bifunctional alkylating anticancer drug that is a rodent carcinogen and a suspected human carcinogen. "	( Hprt mutant frequency and molecular analysis of Hprt mutations in Fischer 344 rats treated with thiotepa. Aidoo, A; Casciano, DA; Chen, T; Heflich, RH; Mittelstaedt, RA, 1999)	1.96
"Thiotepa is an alkylating agent widely used in high-dose chemotherapy. "	( Validation of a therapeutic drug monitoring strategy for thiotepa in a high-dose chemotherapy regimen. Beijnen, JH; Huitema, AD; Mathôt, RA; Rodenhuis, S; Tibben, MM, 2001)	2
"thioTEPA seems to be a potent noncompetitive inhibitor of CYP2B6, with K(i) values of 4.8 +/- 0.3 and 6.2 +/- 0.7 microM for HLMs and recombinant CYP2B6, respectively, values that are within the plasma concentration range of thioTEPA at therapeutic doses (1.1-18.6 microM)."	( Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism. Desta, Z; Flockhart, DA; Rae, JM; Soukhova, NV, 2002)	1.04
"7. Thiotepa is a relatively inexpensive and safe intravesical chemotherapeutic agent which, when used for treatment of existing tumor, will provide a complete response rate of from 35 to 45%."	( Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma. Jordan, AM; Murphy, WM; Soloway, MS, 1989)	0.79
"Thiotepa is an established alkylating agent whose pharmacokinetics in standard doses are well defined. "	( Human plasma pharmacokinetics of thiotepa following administration of high-dose thiotepa and cyclophosphamide. Ackland, SP; Bitran, JD; Choi, KE; Egorin, MJ; Ratain, MJ; Sinkule, JA; Williams, SF, 1988)	2

Excerpt	Reference	Relevance
"Thiotepa has improved engraftment when added to this regimen, however the minimum effective dose (MED) of thiotepa to achieve engraftment while minimizing toxicities has not been well established."	( Feasibility study of busulfan, fludarabine, and thiotepa conditioning regimen for allogeneic hematopoietic stemcell transplantationfor children and young adults with nonmalignant disorders. Cascio, E; Castillo, P; Farhadfar, N; Fort, J; Fraser, A; Horn, B; Lamba, J; Moore-Higgs, G; Slayton, W, 2023)	1.89
"Thiotepa has excellent antileukemic and immunosuppressive activity, and could therefore be a useful drug in the conditioning regimen for patients with advanced hematologic neoplasms."	( Thiotepa and fractionated TBI conditioning prior to allogeneic stem cell transplantation for advanced hematologic malignancies: a phase II single institution trial. Beall, CL; Bunner, P; Devetten, MP; Ericson, SG; Lynch, JP; Qazilbash, MH; Weisenborn, R, 2004)	2.49
"Thiotepa (TT) has long been considered for inclusion in clinical bone marrow transplant (BMT) conditioning regimens in an attempt to prevent allograft rejection and leukemia relapse. "	( Thiotepa improves allogeneic bone marrow engraftment without enhancing stem cell depletion in irradiated mice. Boudewijn, A; Down, JD; Ploemacher, RE; Setroikromo, R; Westerhof, GR, 1998)	3.19
"Thiotepa (TT) has not been reported to cause cardiomyopathy, whereas cyclophosphamide (Cy)-related cardiomyopathy is well characterized. "	( Thiotepa-associated cardiomyopathy during blood or marrow transplantation: association with the female sex and cardiac risk factors. Alidina, A; Anderson, B; Baer, MR; Bambach, B; Barcos, MP; Bernstein, SH; Czuczman, MS; Ford, LA; Lawrence, D; McCarthy, PL; Proulx, GM; Slack, JL; Spangenthal, E; Wetzler, M, 1999)	3.19
"Thiotepa has been used clinically for greater than 30 years but its pharmacokinetics remain poorly defined. "	( Human plasma pharmacokinetics and urinary excretion of thiotepa and its metabolites. Aisner, J; Cohen, BE; Egorin, MJ; Gutierrez, PL; Kohlhepp, EA, 1986)	1.96

Excerpt	Reference	Relevance
"ThioTEPA was found to inhibit CYP2B6 activity in a time- and concentration-dependent manner."	( Inhibition of human CYP2B6 by N,N',N''-triethylenethiophosphoramide is irreversible and mechanism-based. Eichelbaum, M; Richter, T; Schwab, M; Zanger, UM, 2005)	1.05
"Thiotepa was found to produce marked acantholysis in 43 per cent of those studied."	( The effect of chemotherapeutic agents on the ultrastructure of transitional cell carcinoma in tissue culture. Adelstein, E; Haigh, J; Khare, N; Oxenhandler, R; Ross, G; Weaver, D, 1980)	0.98

Excerpt	Reference	Relevance
"ThioTEPA-treated mice subjected to an object recognition test 1, 2, 3, 4, 8, 12, 20 or 30 weeks following treatment demonstrated significant memory deficits at 12 and 20 weeks."	( The chemotherapy agent, thioTEPA, yields long-term impairment of hippocampal cell proliferation and memory deficits but not depression-related behaviors in mice. Gulinello, ME; Mondie, CM; Vandergrift, KA; Weber, ET; Wilson, CL, 2010)	1.39
"Thiotepa treatments should be limited to 90 mg/mo and protracted therapy avoided in elderly men."	( Hematologic effects of intravesicular thiotepa therapy for bladder carcinoma. Coleman, M; Hollister, D, 1980)	1.25
"Thiotepa treatment increased the lacI mutant frequency from 34.8 +/- 4.1 x 10(-6) in control animals to 140.9 +/- 64.8 x 10(-6) (p = 0.0020) and the Hprt mutant frequency from 3.5 +/- 1.5 x 10(-6) to 41.1 +/- 23.2 x 10(-6) (p = 0.0028)."	( Comparison of mutant frequencies and types of mutations induced by thiotepa in the endogenous Hprt gene and transgenic lacI gene of Big Blue rats. Aidoo, A; Casciano, DA; Chen, T; Heflich, RH; Lyn-Cook, LE; Manjanatha, MG; Mittelstaedt, RA; Shelton, SD, 1998)	1.26

Excerpt	Reference	Relevance
" There were no toxic deaths."	( Feasibility and toxicity study of a high-dose chemotherapy regimen for autotransplantation incorporating carboplatin, cyclophosphamide and thiotepa. Baars, JW; Mandjes, I; Pinedo, HM; Richel, DJ; Rodenhuis, S; Schornagel, JH; Vlasveld, LT, 1992)	0.49
" The LD50 of 5 is 270 mg/kg, while that of Thio-TEPA is 18 mg/kg."	( In the search for new anticancer drugs. X. N,N; N',N'-bis(1,2-ethanediyl)-N''-(1-oxyl-2,2,6,6-tetramethyl- 4-piperidinylaminocarbonyl) phosphoric triamide--a new potential anticancer drug of high activity and low toxicity. Li, SW; Sosnovsky, G, 1985)	0.27
"No toxic deaths were reported."	( [High-dosage chemotherapy and the autologous transplantation of peripheral hematopoietic progenitor cells in breast cancer: the initial results, analysis of toxicity and the necessary support means]. Alonso, MC; Amill, B; Bellet, M; Maroto, P; Mendoza, L; Mesía, R; Ojeda, B; Sola Rocabert, C; Tabernero, JM; Verger, G, 1995)	0.29
" This low toxic profile leads to the possibility of future trials with this chemotherapy schedule in other subgroups of patients with breast cancer."	( [High-dosage chemotherapy and the autologous transplantation of peripheral hematopoietic progenitor cells in breast cancer: the initial results, analysis of toxicity and the necessary support means]. Alonso, MC; Amill, B; Bellet, M; Maroto, P; Mendoza, L; Mesía, R; Ojeda, B; Sola Rocabert, C; Tabernero, JM; Verger, G, 1995)	0.29
" It is the authors' conclusion that the portable isolated limb perfusion system achieved all of the required parameters to provide safe and effective treatment for this type of melanoma."	( Safe, compact and portable system for regional chemotherapeutic hyperthermic perfusion procedures. Faddis, D; Fried, SJ; Miller, R; Weaver, FA, 1993)	0.29
" Furthermore, we evaluated the times for hematopoietic reconstitution in a group of five BC patients in the high-risk adjuvant situation who underwent HD chemotherapy and hematopoietic rescue with positive/negative selected stem cells and compared it with our own data from 10 BC patients who, after identical HD therapy, received only positively selected CD34+ cells and 14 patients who, after identical HD therapy, received autografts purged by incubation with toxic ether lipids (ET-18-OCH3)."	( Efficacy and safety of simultaneous immunomagnetic CD34+ cell selection and breast cancer cell purging in peripheral blood progenitor cell samples used for hematopoietic rescue after high-dose therapy. Berdel, WE; Cassens, U; Fietz, T; Hilgenfeld, E; Hoffmann, M; Hoppe, B; Kienast, J; Knauf, WU; Koenigsmann, M; Mohr, M; Sibrowski, W; Thiel, E, 1999)	0.3
" The BAD pump was safe and effective in minimizing nausea and vomiting associated with HDC, and thus, eliminated the need for hospitalization for management of chemotherapy-induced nausea and vomiting."	( Safety and efficacy of a continuous infusion, patient controlled anti-emetic pump to facilitate outpatient administration of high-dose chemotherapy. Belt, R; Coon, J; Cord, M; Dix, S; Geller, R; Howard, S, 1999)	0.3
" The toxic death rate was 1%."	( Toxicity of the high-dose chemotherapy CTC regimen (cyclophosphamide, thiotepa, carboplatin): the Netherlands Cancer Institute experience. Baars, JW; Holtkamp, MJ; Rodenhuis, S; Schornagel, JH; Schrama, JG, 2003)	0.55
" This report shows that conventional-dose palliative chemotherapy regimens may be safe and effective after failure of high-dose chemotherapy."	( Palliative chemotherapy after failure of high-dose chemotherapy in breast cancer--toxicity and efficacy. Baars, JW; de Boer, MM; Rodenhuis, S; Schornagel, JH; Schrama, JG, )	0.13
" TMJ is a safe and effective regimen when used as a part of autologous stem cell transplant for patients with HD and NHL."	( High dose chemotherapy with thiotepa, mitoxantrone and carboplatin (TMJ) followed by autologous stem cell support in 100 consecutive lymphoma patients in a single centre: analysis of efficacy, toxicity and prognostic factors. Ahmed, T; Hoang, A; Kancherla, R; Liu, D; Qureshi, Z; Seiter, K; Waheed, F, 2004)	0.62
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."	( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004)	0.32
" Unfortunately, its adverse effects, mainly hypersensitivity skin reactions and hepatotoxicity, have hampered the use of nevirapine."	( RAT CYP3A and CYP2B1/2 were not associated with nevirapine-induced hepatotoxicity. Abraham, AM; Barr, S; Walubo, A, 2006)	0.33
" These cases demonstrate that it is feasible and safe to perform HSCT in pediatric patients with low nGFR using melphalan- and thiotepa-based preparative therapy."	( Autologous hematopoietic stem cell transplant with melphalan and thiotepa is safe and feasible in pediatric patients with low normalized glomerular filtration rate. Gross, TG; Grovas, A; Klopfenstein, K; Rosselet, R; Termuhlen, AM, 2006)	0.78
" Pharmacogenetic approaches can identify patients who are at risk of experiencing toxic side effects in high-dose chemotherapy."	( Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin. Beijnen, JH; Ekhart, C; Huitema, AD; Rodenhuis, S; Smits, PH, 2008)	0.56
" The conditioning regimen was well tolerated, without any toxic deaths."	( Toxicity of high-dose chemotherapy with etoposide, thiotepa and CY in treating poor-prognosis Ewing's sarcoma family tumors: the experience of the Bambino Gesù Children's Hospital. Cozza, R; De Ioris, MA; De Lurentis, C; De Sio, L; Fidani, P; Ilari, I; Jenkner, A; Milano, GM; Pessolano, R, 2010)	0.61
" This treosulfan-based preparation proved to be safe and effective for thalassemia patients given allogeneic HSCT."	( Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan. Bernardo, ME; Bertaina, A; Caocci, G; Contoli, B; Giorgiani, G; La Nasa, G; Locatelli, F; Mastronuzzi, A; Pagliara, D; Pinto, RM; Piras, E; Vacca, A; Zecca, M, 2012)	0.38
"Serious neurological adverse events (NAE) have occurred during treatment with high-dose thiotepa regimens of children with high-risk solid tumours."	( High-dose thiotepa-related neurotoxicity and the role of tramadol in children. Demirdjian, S; Dufour, C; Laplanche, A; Lemare, F; Maritaz, C; Valteau-Couanet, D, 2018)	1.11
" TBC combined with thiotepa is highly toxic to the skin with various cutaneous manifestations."	( Skin toxicity following treosulfan-thiotepa-fludarabine-based conditioning regimen in non-malignant pediatric patients undergoing hematopoietic stem cell transplantation. Altman Kohl, S; Even-Or, E; Molho-Pessach, V; Stepensky, P; Zaidman, I, 2020)	1.16

Excerpt	Reference	Relevance
" Pharmacokinetic studies have shown that these compounds possess particular affinity towards tumor tissue."	( Toxicity, antitumor activity, and pharmacokinetics of spin-labeled thioTEPA analogs. Djachkovskaya, RF; Emanuel, NM; Konovalova, NP, 1976)	0.49
"A pharmacokinetic study of randomised crossover design was carried out in which eight patients with recurrent stage pTa or pT1 transitional cell carcinoma of the bladder were given thioTEPA (30 mg) in distilled water or in 10% (v/v) Tween 80 (30 ml) intravesically for 2 h, followed 3 months later by the alternative treatment."	( ThioTEPA pharmacokinetics during intravesical chemotherapy and the influence of Tween 80. Bibby, MC; Fenwick, E; Jenkins, WE; Loadman, PM; Masters, JR; McDermott, BJ; Mundy, AR; Shah, PJ, 1990)	1.91
" Linear regression analyses of pharmacokinetic parameters versus myelosuppression revealed statistically significant correlations between thio-TEPA pharmacokinetics and the percentage of reductions in leukocytes and platelets at their mean nadirs."	( Pharmacokinetics of thio-TEPA and TEPA in the conventional dose-range and its correlation to myelosuppressive effects. Hagen, B, 1991)	0.28
" The half-life of thioTEPA ranged from 51."	( Phase I/pharmacokinetic reevaluation of thioTEPA. Cole, D; DeLap, RJ; DeVito, J; Engstrom, PF; LaCreta, F; Litwin, S; O'Dwyer, PJ; Peter, R; Poplack, D; Tartaglia, L, 1991)	0.88
" With this rationale a clinical phase I and pharmacokinetic study of intraperitoneally administered N, N', N'' triethylenethiophosphoramide (thiotepa), an alkylating agent with activity against ovarian carcinoma, was initiated with the objectives of determining the systemic and local toxicities, maximum-tolerated dose, and pharmacokinetic advantage associated with using the drug in this manner."	( Phase I clinical and pharmacokinetic study of thiotepa administered intraperitoneally in patients with advanced malignancies. Egorin, MJ; Runowicz, CD; Salva, K; Tortorello, L; Wadler, S; Wiernik, PH; Zuhowski, EG, 1989)	0.74
" The plasma and cerebrospinal fluid (CSF) pharmacokinetic parameters of TT and its major active metabolite tepa (TP) were also evaluated."	( Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa. Balis, F; Cole, DE; Ettinger, LJ; Gillespie, A; Heideman, RL; Packer, RJ; Reaman, GH; Sam, J; Sato, J; Singher, LJ, 1989)	0.54
" injection site to the systemic circulation and an apparent increase in the elimination half-life (3."	( Single and repeated dose pharmacokinetics of thio-TEPA in patients treated for ovarian carcinoma. Hagen, B; Iversen, T; Nilsen, OG; Walseth, F; Walstad, RA, 1987)	0.27
" We conclude that high-dose thiotepa results in similar pharmacokinetic values to conventional doses with no apparent dose-dependent variation."	( Human plasma pharmacokinetics of thiotepa following administration of high-dose thiotepa and cyclophosphamide. Ackland, SP; Bitran, JD; Choi, KE; Egorin, MJ; Ratain, MJ; Sinkule, JA; Williams, SF, 1988)	0.85
"9 X 10(-4)M, and remained as a level of 10(-6)M for 72 hours with a half-life of 10."	( [Pharmacokinetics of intrathecal chemotherapy and clinical problems]. Fujimoto, T, 1984)	0.27
" The mechanisms of modifications were examined by pharmacokinetic techniques."	( [The pharmacokinetic modification of mutagenesis]. Bratslavskiĭ, VA; Revazova, IuA, 1993)	0.29
" The plasma cyclophosphamide disposition data of these patients were fit by a one-compartment pharmacokinetic model, in which the decline of plasma cyclophosphamide concentration after reaching the initial steady state was modeled as being due to an increase in the clearance rate of cyclophosphamide."	( Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. Black, KC; Chen, TL; Colvin, OM; Grochow, LB; Kennedy, MJ; Noe, DA; Passos-Coelho, JL, 1995)	0.29
"Pharmacokinetic and pharmacodynamic data were collected in 17 women entered in a phase II trial of sequential HDP, and high-dose melphalan and cyclophosphamide/thiotepa/carboplatin."	( The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer. Balmaceda, CM; Egorin, MJ; Hesdorffer, CS; Huang, M; Kaufman, E; Papadopoulos, KP; Troxel, AB; Vahdat, LT, 2001)	0.51
" The degree of neurotoxicity subsequent to HDP was associated with the degree of baseline neuropathy but was not predictable from pharmacokinetic parameters."	( The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer. Balmaceda, CM; Egorin, MJ; Hesdorffer, CS; Huang, M; Kaufman, E; Papadopoulos, KP; Troxel, AB; Vahdat, LT, 2001)	0.31
" The aim of this study was to develop a population pharmacokinetic model for the bioactivation route of CP incorporating the phenomena of both autoinduction and the drug-drug interaction between CP and thioTEPA."	( A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide. Beijnen, JH; Huitema, AD; Mathôt, RA; Rodenhuis, S; Tibben, MM, 2001)	0.71
" Since such treatment is relatively toxic, pharmacokinetic characteristics of total and ultrafiltered platinum, representing different species of platinum complexes formed, were investigated in 29 patients in relation to toxicity."	( Toxicity of high-dose carboplatin: ultrafiltered and not total plasma pharmacokinetics is of clinical relevance. Beyer, J; Jaehde, U; Kloft, C; Siegert, W, 2002)	0.31
" The aim of the current study was to investigate whether the influence of CP on TT metabolism can be described with a population pharmacokinetic model and whether this interaction can be incorporated in an integrated model describing both CP and TT pharmacokinetics."	( Integrated Population Pharmacokinetic Model of both cyclophosphamide and thiotepa suggesting a mutual drug-drug interaction. Beijnen, JH; de Jonge, ME; Huitema, AD; Rodenhuis, S, 2004)	0.56
" The model was successfully incorporated into the previously published pharmacokinetic model for CP, and resulted in comparable parameter estimates for this compound and its metabolite 4OHCP."	( Integrated Population Pharmacokinetic Model of both cyclophosphamide and thiotepa suggesting a mutual drug-drug interaction. Beijnen, JH; de Jonge, ME; Huitema, AD; Rodenhuis, S, 2004)	0.56
" The existence of a mutual pharmacokinetic interaction between CP and TT, as described in our integrated model, may be relevant in clinical practice."	( Integrated Population Pharmacokinetic Model of both cyclophosphamide and thiotepa suggesting a mutual drug-drug interaction. Beijnen, JH; de Jonge, ME; Huitema, AD; Rodenhuis, S, 2004)	0.56
" Doses were adapted on day 3 based on pharmacokinetic analyses of cyclophosphamide, 4-hydroxycyclophosphamide, thiotepa, tepa, and carboplatin done on day 1 using a Bayesian algorithm."	( Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy. Beijnen, JH; de Jonge, ME; Huitema, AD; Rodenhuis, S; Tukker, AC; van Dam, SM, 2005)	0.75
" The aim of this study was to develop a population pharmacokinetic model describing the complex pharmacokinetics of CP, 4OHCP, 2DCECP, and PM when CP is administered in a high-dose combination with thiotepa and carboplatin."	( Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin. Beijnen, JH; de Jonge, ME; Huitema, AD; Rodenhuis, S; van Dam, SM, 2005)	0.71
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
" Relations between allelic variants and elimination pharmacokinetic parameters were evaluated using nonlinear mixed effects modelling (nonmem)."	( Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa. Beijnen, JH; Doodeman, VD; Ekhart, C; Huitema, AD; Rodenhuis, S; Smits, PH, 2009)	0.57

Excerpt	Reference	Relevance
"On a model of transplantable albeolar-mucous RS cancer it is shown that hydrocortisone, desoxycorticosteonre-acetate (DOCA), cyanocobalamine used in combination with folic and nicotinic acids does not lower the cytostatic activity of thiophosphamide and in a number cases even potentiates its action."	( [Effect of corticosteroids, vitamins and their combination with thiophosphamide on the indicators of carbohydrate and electrolyte metabolism of animals with experimental tumors]. Butov, VI; Dunaev, VV, )	0.13
" PDT combined with either adriamycin, MMC or BCG, produced a greater retardation in the growth of the MBT-2 tumor than monotherapy with adriamycin, MMC, BCG or PDT."	( Effects of photodynamic therapy in combination with intravesical drugs in a murine bladder tumor model. Cho, YH; Smith, JA; Straight, RC, 1992)	0.28
" We performed a phase I study of the alkylating agent thiotepa in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), with the goal of dose-escalation of thiotepa."	( Phase I trial of thiotepa in combination with recombinant human granulocyte-macrophage colony-stimulating factor. Hudes, GR; LaCreta, FP; McAleer, C; Miller, LL; Nash, S; O'Dwyer, PJ; Ozols, RF; Schilder, R, 1992)	0.87
"Thirty-five patients with advanced gynecologic malignancies were entered into a phase I study evaluating thio-TEPA in combination with cisplatin (50 mg/m2) intravenously every 4 weeks."	( Phase I evaluation of thio-TEPA in combination with cisplatin for advanced gynecologic malignancies. Edwards, CL; Freedman, RS; Kavanagh, J; Raber, MN; Sandles, LG; Scott, WR; Wharton, JT, 1990)	0.28
"The effects of interferon alone and in combination with either adriamycin, mitomycin C or thiotepa were evaluated for antiproliferative activity for the mouse bladder tumor, MBT-2."	( Effects of interferon in combination with cytotoxic drugs on mouse bladder tumor (MBT-2) growth in vitro and in vivo. Bahnson, R; Ratliff, TL, 1988)	0.5
" This trial was performed to determine if novobiocin, an agent that inhibits DNA repair, could be given with high-dose alkylators."	( Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer. Armstrong, DK; Chen, TL; Clarke, BV; Colvin, OM; Davidson, NE; Grochow, LB; Huelskamp, AM; Kennedy, MJ; Ohly, K, 1995)	0.29
"Novobiocin may be given with high-dose alkylators in doses that produce plasma levels that augment the activity of these cytotoxics in experimental models."	( Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer. Armstrong, DK; Chen, TL; Clarke, BV; Colvin, OM; Davidson, NE; Grochow, LB; Huelskamp, AM; Kennedy, MJ; Ohly, K, 1995)	0.29
" We have used clonogenic cell survival assays and DNA flow cytometry to examine the effect of paclitaxel combined with melphalan, thiotepa, or cisplatin on the survival and cell-cycle parameters of human lung A549 and breast MCF-7 adenocarcinoma cells."	( Sequence dependence of paclitaxel (Taxol) combined with cisplatin or alkylators in human cancer cells. Cook, JA; Fisher, J; Liebmann, JE; Teague, D, 1994)	0.49
"High-dose chemotherapy given with autologous bone marrow support has resulted in significant tumor responses in the majority of patients with metastatic breast cancer, a minority of which are durable."	( Dose escalation of mitoxantrone given with thiotepa and autologous bone marrow transplantation for metastatic breast cancer. Adkins, D; Bowers, C; Dunphy, F; Harrison, B; LeMaistre, CF; Spitzer, G, 1993)	0.55
"Cyclophosphamide (CP) is widely used in high-dose chemotherapy regimens in combination with thioTEPA."	( A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide. Beijnen, JH; Huitema, AD; Mathôt, RA; Rodenhuis, S; Tibben, MM, 2001)	0.74
" The potential application of administering irofulven in combination with aziridine-containing chemotherapeutic agents was evaluated in this study."	( Enhanced antitumor activity of irofulven in combination with thiotepa or mitomycin C. Estes, L; Kelner, MJ; McMorris, TC; Rojas, RJ; Trani, NA, 2002)	0.56
"Human lung carcinoma MV522 cells and BALB/c athymic mice bearing the human lung carcinoma MV522 xenograft were used to evaluate the activity of irofulven in combination with aziridine-containing drugs."	( Enhanced antitumor activity of irofulven in combination with thiotepa or mitomycin C. Estes, L; Kelner, MJ; McMorris, TC; Rojas, RJ; Trani, NA, 2002)	0.56
"Irofulven in combination with either thiotepa or mitomycin C demonstrated a strong synergistic (supraadditive) activity both in vitro and in vivo, that exceeded results obtained with monotherapy at the same or higher doses of these agents."	( Enhanced antitumor activity of irofulven in combination with thiotepa or mitomycin C. Estes, L; Kelner, MJ; McMorris, TC; Rojas, RJ; Trani, NA, 2002)	0.83
"These results indicate that the therapeutic activity of irofulven is enhanced when combined with mitomycin C or thiotepa, and further evaluation of these combinations is therefore warranted."	( Enhanced antitumor activity of irofulven in combination with thiotepa or mitomycin C. Estes, L; Kelner, MJ; McMorris, TC; Rojas, RJ; Trani, NA, 2002)	0.77
"The objectives of this phase II protocol were: 1) to determine the clinical activity of thiotepa combined with cisplatin in suboptimally debulked advanced epithelial ovarian carcinoma as first-line chemotherapy, 2) to determine by surgery the response after 6 courses of chemotherapy, and 3) to identify the regimen's qualitative and quantitative toxicities."	( Thiotepa in combination with cisplatin for primary epithelial ovarian cancer: a phase II study. Freedman, RS; Gordinier, ME; Kavanagh, JJ; Kudelka, AP; Wharton, JT, )	1.8
"The pharmacokinetics of TT, when administered in combination with CP, were successfully described."	( Integrated Population Pharmacokinetic Model of both cyclophosphamide and thiotepa suggesting a mutual drug-drug interaction. Beijnen, JH; de Jonge, ME; Huitema, AD; Rodenhuis, S, 2004)	0.56
" The aim of this study was to develop a population pharmacokinetic model describing the complex pharmacokinetics of CP, 4OHCP, 2DCECP, and PM when CP is administered in a high-dose combination with thiotepa and carboplatin."	( Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin. Beijnen, JH; de Jonge, ME; Huitema, AD; Rodenhuis, S; van Dam, SM, 2005)	0.71
" In conclusion, although TH produced only a moderate effect against BCL1 leukemia when used alone, its combination with CY is promising and should be tested further in allogeneic murine models and clinical studies."	( The effect of high-dose thiotepa, alone or in combination with other chemotherapeutic agents, on a murine B-cell leukemia model simulating autologous stem cell transplantation. Abdul-Hai, A; Ergas, D; Resnick, IB; Shapira, MY; Slavin, S; Weiss, L, 2007)	0.65
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."	( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012)	0.38

Excerpt	Reference	Relevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Excerpt	Relevance	Reference
"Studies on the effect of different regimens of chemotherapy and local x-ray irradiation on the kinetics of the growth of Walker carcinosarcoma and Heren carcinoma have demonstrated that in the range of dosage of alkylating action drugs under study and also irradiation, the time of the recurrence onset depends on the therapeutic regimen."	( [Effect of different regimens of chemotherapy and x-ray irradiation on the kinetics of experimental tumor growth]. Emanuél', NM; Konovalova, NP; Parkanskiĭ, MI, 1975)	0.25
" A combination of chemical substances and the dosage of single administration were as follows: thio-TEPA--100--150 mg + methotrexate 75--100 mg; thio-TEPA--100--150 mg + 5-fluoruracil--1000 mg; cyclophosphane--2000 mg + methotrexate--75--100 mg; cyclophosphane--1600 mg + methotrexate--75--100 mg + 5-fluoruracil--750 mg."	( [Endolymphatic chemotherapy of cervix neoplasms]. Birbraer, VM; Bordiushkov, IuN; Il'inskaia, EG; Pankov, AK; Sidorenko, IuS, 1976)	0.26
" Haematologic toxicity is greater in the CMF group, requiring more frequent dosage reductions."	( Randomized trial of adjuvant chemotherapy for operable breast cancer comparing i.v. CMF to an epirubicin-containing regimen [see comment]. Bonichon, F; Chauvergne, J; Dilhuydy, JM; Durand, M; Mauriac, L, 1992)	0.28
" Different dosage schedules and methods require further study."	( Intravesical chemotherapy. Treatment selection, techniques, and results. Richie, JP, 1992)	0.28
" The great interindividual variation encountered in the serum pharmacokinetics of TEPA may be of clinical importance and represents a further indication that pharmacokinetically guided dosing of thio-TEPA could be valuable."	( Long-term pharmacokinetics of thio-TEPA, TEPA and total alkylating activity following i.v. bolus administration of thio-TEPA in ovarian cancer patients. Hagen, B; Neverdal, G; Nilsen, OG; Walstad, RA, 1990)	0.28
" We advocate further investigation of this pharmacokinetic-pharmacodynamic relationship so as to establish individualized dosing of thio-TEPA."	( Pharmacokinetics of thio-TEPA and TEPA in the conventional dose-range and its correlation to myelosuppressive effects. Hagen, B, 1991)	0.28
") was administered just prior to an alkylating agent, the combination treatment produced significantly more tumor cell killing across the dosage range of each alkylating agent tested compared with the alkylating agent alone."	( Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma. Bubley, G; Coleman, CN; Eder, JP; Frei, E; Herman, TS; Holden, SA; Tanaka, J; Teicher, BA, 1991)	0.28
" In the FSaIIC murine fibrosarcoma tumor system, 5 intraperitoneal (IP) injections of 50 mg/kg of lonidamine over 36 hours increased the tumor cell kill by cisplatin, carboplatin, D-tetraplatin, melphalan and BCNU approximately two- to threefold over the dosage ranges of each drug tested when the antitumor agents were given IP immediately after the third lonidamine injection."	( Modulation of alkylating agents by lonidamine in vivo. Frei, E; Herman, TS; Holden, SA; Teicher, BA, 1991)	0.28
" When beta-radiation or Thiotepa is used there is a general consensus on the dosage for each of these."	( Treatment of pterygia in Queensland. Hirst, LW; Sebban, A, 1991)	0.59
" Up to now, most of the chemicals tested have shown additive effects when combined with doses of the ascending part of the dose-response curve and potentiating effects when combined with doses of its descending part."	( The induction of reciprocal translocations in mouse germ cells by chemicals and ionizing radiations. II. Combined effects of mitomycin C or thio-tepa with two doses of gamma-rays. Andrieu, JM; De Luca, JC; Dulout, FN; Furnus, CC; Ulrich, MA, 1990)	0.28
" This regimen can be safely administered on an outpatient basis, with adequate control of gastrointestinal symptoms achieved by standard antiemetics and intermittent dosing with meals."	( Phase I trial of escalating pentoxifylline dose with constant dose thiotepa. Dezube, BJ; Eder, JP; Pardee, AB, 1990)	0.52
"The principles of dose-response and combination chemotherapy were basic to the design of the initial curative standard-dose treatment regimens for leukemias, lymphomas, and testis cancer."	( A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients. Burke, J; Eder, JP; Elias, A; Frei, E; Hunt, M; Schnipper, LE; Schryber, SM; Shea, TC; Siegel, R; Teicher, BA, 1990)	0.55
" The dose-response relationships after treatment with doses of 20, 40 and 60 mg/kg of the compound as well as the combined effect of BLM and gamma-rays and BLM and thio-tepa (TT) were studied."	( The induction of reciprocal translocations in mouse germ cells by chemicals and ionizing radiations. I. Dose-response relationships and combined effects of bleomycin with thio-tepa and gamma-rays. Andrieu, JM; De Luca, JC; Dulout, FN, 1988)	0.27
"We defined the plasma and tissue concentrations and pharmacokinetics of SL-O-TT, a spin-labeled analog of thio-TEPA, in 35-44-g male Swiss Webster mice that had received spin-labeled thio-TEPA at a dosage of 10 mg/kg."	( On the search for new anticancer drugs 14: the plasma pharmacokinetics and tissue distribution of spin-labeled thio-TEPA (SL-O-TT). Cohen, BE; Davis, TA; Egorin, MJ; Gutierrez, PL; Sosnovsky, G, 1985)	0.27
" Dosage of thiotepa was significantly related to percentage of sperm head morphological abnormalities assayed by light microscopy."	( Toxicity of thiotepa on mouse spermatogenesis as determined by dual-parameter flow cytometry. Baer, RK; Evenson, DP; Gesch, RW; Jost, LK, 1986)	1.04
" It was shown that the dose-response relationships and corresponding regression coefficients were similar when the in vivo and in vitro results were compared."	( [Quantitative comparison of the cytogenetic effect of thiophosphamide during in vivo and in vitro action on monkey lymphocytes]. Kuzin, SM; Popandopulo, PG; Stukalov, SV, 1987)	0.27
" Interindividual dosing of thio-TEPA based on an initial AUC estimation is suggested."	( Pharmacokinetics of thio-TEPA at two different doses. Hagen, B; Nilsen, OG; Walstad, RA, 1988)	0.27
" Females, however, exposed to the same dosage for the same length of time were partially fertile."	( Chemosterilization of the tropical house mosquito Culex pipiens fatigans Wied.: laboratory and field cage studies. Grover, KK; LaBrecque, GC; Patterson, RS; Sharma, VP, 1973)	0.25
" These patients with progressive bladder carcinoma appeared to be unaffected by intravesical thiotepa in the dosage used."	( Intravesical thiotepa prophylaxis of superficial bladder cancer. A follow-up study. Fosså, SD; Miller, A; Stenwig, AE, 1983)	0.85
" injection of arsenic trioxide, at the dosage range of 1/4 to 1/40 LD50 into hybrid mice (CBA X C57B1/6J)F1, no induction of dominant lethals in male germ cells was observed."	( [Arsenic trioxide inhibition of the thiophosphamide induction of mutations in mouse germ and somatic cells]. Kozachenko, VI; Pashin, IuV; Toroptsev, SN, 1984)	0.27
" The treatment with hydrazine sulfate (60 mg/kg) plus thiophosphamide (1 mg/kg) resulted in suppression of tumor growth up to 90%, the dosage of thiophosphamide being therapeutically ineffective."	( [Selective action of hydrazine sulfate in combination with thiophosphamide on tumor cell mitochondria]. Filov, VA; Golovatova, VA; Tret'iakov, AV, 1982)	0.26
" Continuing maintenance therapy was required in the majority but, with the passage of time, the dosage could be progressively reduced, suggesting a cumulative effect of treatment."	( Early multiple-dose adjuvant thiotepa in the control of multiple and rapid T1 tumour neogenesis. Blandy, JP; England, HR; Flynn, JT; Paris, AM, 1981)	0.55
" We determined the pharmacokinetics of thioTEPA and its metabolite TEPA during first-dose infusion of thioTEPA 150-250 mg/m2 given daily for 3 days in combination with busulfan and cyclophosphamide, and evaluated the results for correlations with toxicity and dosing strategies."	( Dosing of thioTEPA for myeloablative therapy. Dimopoulos, M; Estrov, Z; Ippoliti, C; Madden, T; Przepiorka, D, 1995)	0.96
" A clear dose-response relationship was evident between the number of CD34+ cells per kilogram infused between the number of CD34+ cells per kilogram infused and neutrophil and platelet engraftment kinetics."	( An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Allen, C; Birch, R; Hazelton, B; Palmer, P; Schwartzberg, L; Weaver, CH; West, W, 1995)	0.29
" The validated limited sampling model provides a starting point for future pharmacokinetic studies in a larger population of patients, which might lead to more insight into the relationships with the pharmacodynamic outcome of carboplatin and may help in achieving more rational dosing of patients on the basis of an AUC determination."	( Validation of a limited sampling model for carboplatin in a high-dose chemotherapy combination. Beijnen, JH; Maes, RA; Rodenhuis, S; van Tellingen, O; van Warmerdam, LJ, 1994)	0.29
" In all treatment arms the dosage was 30 mg thiotepa in 50 ml saline."	( The effect of intravesical thiotepa on tumour recurrence after endoscopic treatment of newly diagnosed superficial bladder cancer. A further report with long-term follow-up of a Medical Research Council randomized trial. Medical Research Council Working P , 1994)	0.85
" The steep in vitro dose-response curve of thiotepa and the long durations of response or SD observed with the dose reported here suggest that moderate-dose to high-dose thiotepa with cytokine support or autologous bone marrow rescue may be associated with an improved response rate to this agent."	( A phase II evaluation of thiotepa in pediatric central nervous system malignancies. Allen, JC; Balis, FM; Gillespie, A; Heideman, RL; Horowitz, ME; Kovnar, EH; Lange, B; Packer, RJ; Reaman, GH; Steinberg, SM, 1993)	0.85
" The optimal dosage and schedule was 40 mg kg-1 daily for 5 days."	( Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts. Ardouin, P; Bénard, J; Bissery, MC; Boland, I; Bressac-de-Paillerets, B; Gouyette, A; Gyergyay, F; Morizet, J; Terrier-Lacombe, MJ; Vassal, G; Vénuat, AM, 1996)	0.29
" The EMT-6/PRK5 beta 1E tumor was markedly resistant to a dosage range of cyclophosphamide, cisplatin, melphalan and thiotepa compared with the EMT-6/Parent tumor."	( Transforming growth factor-beta 1 overexpression produces drug resistance in vivo: reversal by decorin. Ara, G; Herbst, RS; Ikebe, M; Keyes, SR; Teicher, BA, )	0.34
" These data suggest that within the high-dose range for preparative therapy, a steep dose-response may exist for breast cancer."	( A novel four-drug ablative regimen with hemopoietic stem cell rescue for patients with breast cancer: a phase II study. Burns, LJ; Gingrich, RD; Hohl, R; Joyce, J; Lee, CK; Scott, S; Tamaki, K; Wen, BC, 1999)	0.3
" infusion via an ambulatory infusion pump with patient-activated intermittent dosing (BAD pump) for prevention of acute and delayed nausea/vomiting in patients receiving high-dose chemotherapy (HDC) for peripheral blood progenitor cell (PBPC) mobilization (MOB) or prior to autologous PBPC rescue."	( Safety and efficacy of a continuous infusion, patient controlled anti-emetic pump to facilitate outpatient administration of high-dose chemotherapy. Belt, R; Coon, J; Cord, M; Dix, S; Geller, R; Howard, S, 1999)	0.3
" On the other hand, bacillus Calmette-Guerin (BCG) currently appears to be the most effective agent for intravesical use, especially in patients with high grade and stage neoplasms but the optimum strain, dosage and duration schedule have not been determined."	( Intravesical therapy of superficial bladder cancer. Melekos, MD; Moutzouris, GD, 2000)	0.31
" The Bayesian method may be very instrumental to execute pharmacokinetic guided dosing for carboplatin."	( Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods. Beijnen, JH; Huitema, AD; Mathôt, RA; Rodenhuis, S; Schellens, JH; Tibben, MM, 2000)	0.31
" CNS relapse and neurotoxicity in patients with acute lymphoblastic leukaemia, especially younger children, may be reduced by using age-related dosing of intrathecal MTX and Ara-C."	( Intrathecal chemotherapy with antineoplastic agents in children. Biagi, E; Conter, V; Lazzareschi, I; Milani, M; Riccardi, R; Ruggiero, A; Sparano, P, 2001)	0.31
" The aim of this study was to develop and validate a pharmacokinetically guided dosing strategy with the sum of the thiotepa and tepa area under the concentration-time curve (AUC) as the target parameter."	( Validation of a therapeutic drug monitoring strategy for thiotepa in a high-dose chemotherapy regimen. Beijnen, JH; Huitema, AD; Mathôt, RA; Rodenhuis, S; Tibben, MM, 2001)	0.77
" It is concluded that cyclophosphamide and thiotepa in obese patients should not be dosed on the basis of BSA incorporating TBW since the patient will be overexposed."	( Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin. Beijnen, JH; De Jonge, ME; Mathôt, RA; Rodenhuis, S; Van Dam, SM, 2002)	0.8
" Timing and dosage are also considered."	( SOME PROBLEMS IN THE CHEMOTHERAPY OF SOLID TUMOURS. ARONOVITCH, M; GROSZMAN, M; KAHANA, LM, 1964)	0.24
"Bayesian pharmacokinetically guided dosing for CTC was feasible and led to a marked reduction in variability of exposure."	( Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy. Beijnen, JH; de Jonge, ME; Huitema, AD; Rodenhuis, S; Tukker, AC; van Dam, SM, 2005)	0.54
" The tumours with a TOP2A amplification contributed hardly to this difference, suggesting that TOP2A amplification is not the cause of the steep dose-response curve for anthracyclines in breast cancer."	( Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy. Bontenbal, M; de Vries, EG; Hannemann, J; Hupperets, P; Kristel, P; Nooij, MA; Rodenhuis, S; Smit, WM; van de Vijver, MJ; van der Wall, E; van Hoesel, QG; van Tinteren, H; Voest, EE, 2006)	0.33
" These results unveiled that the selection of cytotoxic agents and increasing their dosage might be of great importance in the respect of eliminating CSCs."	( DNA methyltransferase inhibitor CDA-2 synergizes with high-dose thiotepa and paclitaxel in killing breast cancer stem cells. Di, L; Jia, J; Lu, Z; Ma, B; Ren, J; Song, G; Wang, X; Yu, J; Yuan, Y; Zhou, X; Zhu, Y, 2011)	0.61
"To evaluate whether blood-based genotoxicity endpoints can provide temporal and dose-response data within the low-dose carcinogenic range that could contribute to carcinogenic mode of action (MoA) assessments, we evaluated the sensitivity of flow cytometry-based micronucleus and Pig-a gene mutation assays at and below tumorigenic dose rate 50 (TD50) levels."	( Pig-a gene mutation and micronucleated reticulocyte induction in rats exposed to tumorigenic doses of the leukemogenic agents chlorambucil, thiotepa, melphalan, and 1,3-propane sultone. Avlasevich, SL; Bemis, JC; Cottom, J; Dertinger, SD; Macgregor, JT; Mereness, J; Phonethepswath, S; Torous, DK, 2014)	0.6
"Treatment for malignant embryonal brain tumors in young children usually employs cycles of standardly dosed cisplatinum followed by high-dose carboplatinum-containing conditioning with single or tandem autologous stem cell rescue (HDC-ASCR)."	( Changes in glomerular filtration rate and clinical course after sequential doses of carboplatin in children with embryonal brain tumors undergoing autologous stem cell transplantation. Almutereen, M; Elborai, Y; Hafez, H; Lee, MA; Lehmann, L; Maher, OM, 2020)	0.56
" So, larger scale studies are needed to clarify the best approach to carboplatin dosing to insure the optimal balance between efficacy and toxicity."	( Changes in glomerular filtration rate and clinical course after sequential doses of carboplatin in children with embryonal brain tumors undergoing autologous stem cell transplantation. Almutereen, M; Elborai, Y; Hafez, H; Lee, MA; Lehmann, L; Maher, OM, 2020)	0.56
" To more thoroughly investigate the dose-response relationships, benchmark dose (BMD) analyses were performed with PROAST software."	( Pig-a gene mutation assay study design: critical assessment of 3- versus 28-day repeat-dose treatment schedules. Dertinger, SD; Elhajouji, A; Hove, TT; Martus, H; O'Connell, O, 2020)	0.56

Class	Description
aziridines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASE	Homo sapiens (human)	Potency	22.3872	0.0040	23.8416	100.0000	AID485290
Luciferase	Photinus pyralis (common eastern firefly)	Potency	14.8127	0.0072	15.7588	89.3584	AID624030
acetylcholinesterase	Homo sapiens (human)	Potency	58.5877	0.0025	41.7960	15,848.9004	AID1347395; AID1347397; AID1347398; AID1347399
thioredoxin reductase	Rattus norvegicus (Norway rat)	Potency	89.1251	0.1000	20.8793	79.4328	AID588453
hypoxia-inducible factor 1 alpha subunit	Homo sapiens (human)	Potency	64.9933	3.1890	29.8841	59.4836	AID1224846
RAR-related orphan receptor gamma	Mus musculus (house mouse)	Potency	3.6237	0.0060	38.0041	19,952.5996	AID1159521
GALC protein	Homo sapiens (human)	Potency	1.5849	28.1838	28.1838	28.1838	AID1159614
TDP1 protein	Homo sapiens (human)	Potency	9.7398	0.0008	11.3822	44.6684	AID686978; AID686979
GLI family zinc finger 3	Homo sapiens (human)	Potency	47.5836	0.0007	14.5928	83.7951	AID1259368; AID1259369
AR protein	Homo sapiens (human)	Potency	54.1749	0.0002	21.2231	8,912.5098	AID1259243; AID743035; AID743042
nuclear receptor subfamily 1, group I, member 3	Homo sapiens (human)	Potency	10.8773	0.0010	22.6508	76.6163	AID1224838; AID1224893
progesterone receptor	Homo sapiens (human)	Potency	0.0041	0.0004	17.9460	75.1148	AID1346795
regulator of G-protein signaling 4	Homo sapiens (human)	Potency	89.1251	0.5318	15.4358	37.6858	AID504845
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	42.0735	0.0123	7.9835	43.2770	AID1645841
EWS/FLI fusion protein	Homo sapiens (human)	Potency	10.6266	0.0013	10.1577	42.8575	AID1259252; AID1259253; AID1259255; AID1259256
glucocorticoid receptor [Homo sapiens]	Homo sapiens (human)	Potency	9.2237	0.0002	14.3764	60.0339	AID720691; AID720692
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	76.7141	0.0030	41.6115	22,387.1992	AID1159552; AID1159553
retinoid X nuclear receptor alpha	Homo sapiens (human)	Potency	46.0117	0.0008	17.5051	59.3239	AID1159527
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	39.8712	0.0015	30.6073	15,848.9004	AID1224841; AID1224842; AID1224848; AID1224849
farnesoid X nuclear receptor	Homo sapiens (human)	Potency	51.6260	0.3758	27.4851	61.6524	AID743217
pregnane X nuclear receptor	Homo sapiens (human)	Potency	67.6173	0.0054	28.0263	1,258.9301	AID1346982; AID720659
G	Vesicular stomatitis virus	Potency	29.7858	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2D6	Homo sapiens (human)	Potency	37.4980	0.0010	8.3798	61.1304	AID1645840
peroxisome proliferator activated receptor gamma	Homo sapiens (human)	Potency	64.9933	0.0010	19.4141	70.9645	AID743191
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	7.9433	0.0355	20.9770	89.1251	AID504332
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a	Homo sapiens (human)	Potency	57.4322	0.0017	23.8393	78.1014	AID743083
thyroid stimulating hormone receptor	Homo sapiens (human)	Potency	2.8784	0.0016	28.0151	77.1139	AID1259385
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a	Homo sapiens (human)	Potency	57.9253	19.7391	45.9784	64.9432	AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)	Homo sapiens (human)	Potency	57.9253	0.0578	21.1097	61.2679	AID1159526
Histone H2A.x	Cricetulus griseus (Chinese hamster)	Potency	133.7010	0.0391	47.5451	146.8240	AID1224845
hemoglobin subunit beta	Homo sapiens (human)	Potency	2.5119	0.3162	9.0861	31.6228	AID910
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1	Homo sapiens (human)	Potency	10.0000	0.0018	15.6638	39.8107	AID894
vitamin D3 receptor isoform VDRA	Homo sapiens (human)	Potency	84.2789	0.3548	28.0659	89.1251	AID504847
chromobox protein homolog 1	Homo sapiens (human)	Potency	4.4668	0.0060	26.1688	89.1251	AID540317
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	37.0152	0.0003	23.4451	159.6830	AID743065; AID743067
heat shock protein beta-1	Homo sapiens (human)	Potency	57.9253	0.0420	27.3789	61.6448	AID743210
serine/threonine-protein kinase PLK1	Homo sapiens (human)	Potency	42.2841	0.1683	16.4040	67.0158	AID720504
nuclear factor erythroid 2-related factor 2 isoform 1	Homo sapiens (human)	Potency	35.7123	0.0006	27.2152	1,122.0200	AID743202; AID743219
DNA polymerase iota isoform a (long)	Homo sapiens (human)	Potency	89.1251	0.0501	27.0736	89.1251	AID588590
geminin	Homo sapiens (human)	Potency	17.9714	0.0046	11.3741	33.4983	AID624296; AID624297
survival motor neuron protein isoform d	Homo sapiens (human)	Potency	11.2202	0.1259	12.2344	35.4813	AID1458
cytochrome P450 3A4 isoform 1	Homo sapiens (human)	Potency	39.8107	0.0316	10.2792	39.8107	AID884; AID885
lamin isoform A-delta10	Homo sapiens (human)	Potency	10.0000	0.8913	12.0676	28.1838	AID1487
Gamma-aminobutyric acid receptor subunit pi	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Interferon beta	Homo sapiens (human)	Potency	29.7858	0.0033	9.1582	39.8107	AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	29.7858	0.0123	8.9648	39.8107	AID1645842
Cellular tumor antigen p53	Homo sapiens (human)	Potency	16.3115	0.0023	19.5956	74.0614	AID651631; AID720552
Gamma-aminobutyric acid receptor subunit beta-1	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit delta	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-5	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-3	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-1	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-2	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-4	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-3	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-6	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-3	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
GABA theta subunit	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	29.7858	0.0123	8.9648	39.8107	AID1645842
Gamma-aminobutyric acid receptor subunit epsilon	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	29.7858	0.0123	8.9648	39.8107	AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	133.0000	0.2000	5.6774	10.0000	AID1473741
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	422.6667	0.1100	7.1903	10.0000	AID1443980; AID1449628; AID1473738
Cytochrome P450 2B1	Rattus norvegicus (Norway rat)	Ki	31.0000	0.0800	2.3100	5.8000	AID589176
Cytochrome P450 2B6	Homo sapiens (human)	Ki	26.1000	0.0004	1.4160	10.0000	AID589234; AID589243
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle G2/M phase transition	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
ER overload response	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
in utero embryonic development	Cellular tumor antigen p53	Homo sapiens (human)
somitogenesis	Cellular tumor antigen p53	Homo sapiens (human)
release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic progenitor cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
T cell proliferation involved in immune response	Cellular tumor antigen p53	Homo sapiens (human)
B cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
T cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
response to ischemia	Cellular tumor antigen p53	Homo sapiens (human)
nucleotide-excision repair	Cellular tumor antigen p53	Homo sapiens (human)
double-strand break repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
protein import into nucleus	Cellular tumor antigen p53	Homo sapiens (human)
autophagy	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
Ras protein signal transduction	Cellular tumor antigen p53	Homo sapiens (human)
gastrulation	Cellular tumor antigen p53	Homo sapiens (human)
neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
protein localization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA replication	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
determination of adult lifespan	Cellular tumor antigen p53	Homo sapiens (human)
mRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
rRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
response to salt stress	Cellular tumor antigen p53	Homo sapiens (human)
response to inorganic substance	Cellular tumor antigen p53	Homo sapiens (human)
response to X-ray	Cellular tumor antigen p53	Homo sapiens (human)
response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of gene expression	Cellular tumor antigen p53	Homo sapiens (human)
cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
viral process	Cellular tumor antigen p53	Homo sapiens (human)
glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
cerebellum development	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell growth	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
mitotic G1 DNA damage checkpoint signaling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of telomere maintenance via telomerase	Cellular tumor antigen p53	Homo sapiens (human)
T cell differentiation in thymus	Cellular tumor antigen p53	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
regulation of tissue remodeling	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV	Cellular tumor antigen p53	Homo sapiens (human)
multicellular organism growth	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of mitochondrial membrane permeability	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
entrainment of circadian clock by photoperiod	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial DNA repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
transcription initiation-coupled chromatin remodeling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of proteolysis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
response to antibiotic	Cellular tumor antigen p53	Homo sapiens (human)
fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
circadian behavior	Cellular tumor antigen p53	Homo sapiens (human)
bone marrow development	Cellular tumor antigen p53	Homo sapiens (human)
embryonic organ development	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Cellular tumor antigen p53	Homo sapiens (human)
protein stabilization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of helicase activity	Cellular tumor antigen p53	Homo sapiens (human)
protein tetramerization	Cellular tumor antigen p53	Homo sapiens (human)
chromosome organization	Cellular tumor antigen p53	Homo sapiens (human)
neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic stem cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
type II interferon-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
cardiac septum morphogenesis	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of programmed necrotic cell death	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Cellular tumor antigen p53	Homo sapiens (human)
thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
necroptotic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to xenobiotic stimulus	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to ionizing radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV-C	Cellular tumor antigen p53	Homo sapiens (human)
stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to actinomycin D	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
replicative senescence	Cellular tumor antigen p53	Homo sapiens (human)
oxidative stress-induced premature senescence	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
oligodendrocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of execution phase of apoptosis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of G1 to G0 transition	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of miRNA processing	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of pentose-phosphate shunt	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
regulation of fibroblast apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2B6	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2B6	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2B6	Homo sapiens (human)
cellular ketone metabolic process	Cytochrome P450 2B6	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2B6	Homo sapiens (human)
inositol phosphate metabolic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
xenobiotic metabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of gene expression	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bile acid and bile salt transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
heme catabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic export from cell	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transepithelial transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
leukotriene transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
transcription cis-regulatory region binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
core promoter sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
TFIID-class transcription factor complex binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
protease binding	Cellular tumor antigen p53	Homo sapiens (human)
p53 binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity	Cellular tumor antigen p53	Homo sapiens (human)
mRNA 3'-UTR binding	Cellular tumor antigen p53	Homo sapiens (human)
copper ion binding	Cellular tumor antigen p53	Homo sapiens (human)
protein binding	Cellular tumor antigen p53	Homo sapiens (human)
zinc ion binding	Cellular tumor antigen p53	Homo sapiens (human)
enzyme binding	Cellular tumor antigen p53	Homo sapiens (human)
receptor tyrosine kinase binding	Cellular tumor antigen p53	Homo sapiens (human)
ubiquitin protein ligase binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase regulator activity	Cellular tumor antigen p53	Homo sapiens (human)
ATP-dependent DNA/DNA annealing activity	Cellular tumor antigen p53	Homo sapiens (human)
identical protein binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase binding	Cellular tumor antigen p53	Homo sapiens (human)
protein heterodimerization activity	Cellular tumor antigen p53	Homo sapiens (human)
protein-folding chaperone binding	Cellular tumor antigen p53	Homo sapiens (human)
protein phosphatase 2A binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Cellular tumor antigen p53	Homo sapiens (human)
14-3-3 protein binding	Cellular tumor antigen p53	Homo sapiens (human)
MDM2/MDM4 family protein binding	Cellular tumor antigen p53	Homo sapiens (human)
disordered domain specific binding	Cellular tumor antigen p53	Homo sapiens (human)
general transcription initiation factor binding	Cellular tumor antigen p53	Homo sapiens (human)
molecular function activator activity	Cellular tumor antigen p53	Homo sapiens (human)
promoter-specific chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2B6	Homo sapiens (human)
iron ion binding	Cytochrome P450 2B6	Homo sapiens (human)
testosterone 16-alpha-hydroxylase activity	Cytochrome P450 2B6	Homo sapiens (human)
heme binding	Cytochrome P450 2B6	Homo sapiens (human)
testosterone 16-beta-hydroxylase activity	Cytochrome P450 2B6	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 2B6	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 2B6	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 2B6	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 2B6	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2B6	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2B6	Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
nuclear body	Cellular tumor antigen p53	Homo sapiens (human)
nucleus	Cellular tumor antigen p53	Homo sapiens (human)
nucleoplasm	Cellular tumor antigen p53	Homo sapiens (human)
replication fork	Cellular tumor antigen p53	Homo sapiens (human)
nucleolus	Cellular tumor antigen p53	Homo sapiens (human)
cytoplasm	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrion	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial matrix	Cellular tumor antigen p53	Homo sapiens (human)
endoplasmic reticulum	Cellular tumor antigen p53	Homo sapiens (human)
centrosome	Cellular tumor antigen p53	Homo sapiens (human)
cytosol	Cellular tumor antigen p53	Homo sapiens (human)
nuclear matrix	Cellular tumor antigen p53	Homo sapiens (human)
PML body	Cellular tumor antigen p53	Homo sapiens (human)
transcription repressor complex	Cellular tumor antigen p53	Homo sapiens (human)
site of double-strand break	Cellular tumor antigen p53	Homo sapiens (human)
germ cell nucleus	Cellular tumor antigen p53	Homo sapiens (human)
chromatin	Cellular tumor antigen p53	Homo sapiens (human)
transcription regulator complex	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex	Cellular tumor antigen p53	Homo sapiens (human)
plasma membrane	Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)
endoplasmic reticulum membrane	Cytochrome P450 2B6	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2B6	Homo sapiens (human)
cytoplasm	Cytochrome P450 2B6	Homo sapiens (human)
plasma membrane	Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)
plasma membrane	Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508628	Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1508629	Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508627	Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347112	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID139532	In vivo evaluation of test/control survival against P388 lymphocytic leukemia in CD2F1 male mice at dose 3 mg/kg; 16.8 / 9.2	1984	Journal of medicinal chemistry, Jun, Volume: 27, Issue:6	In the search for new anticancer drugs. 9. Synthesis and anticancer activity of spin-labeled analogues of N,N:N',N':N",N"-Tri-1,2-ethanediylphosphoric triamide and N,N:N',N':N",N"-tri-1,2-ethanediylphosphorothioic triamide.
AID589243	Mechanism based inhibition of human cytochrome P450 2B6 measured by bupropion hydroxylation using a recombinant system	2005	Current drug metabolism, Oct, Volume: 6, Issue:5	Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID588218	FDA HLAED, lactate dehydrogenase (LDH) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID588217	FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID589234	Mechanism based inhibition of human cytochrome P450 2B6	2005	Current drug metabolism, Oct, Volume: 6, Issue:5	Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID364039	Cytotoxicity against human MCF7 cells after 96 hrs by microtiter assay	2008	European journal of medicinal chemistry, Sep, Volume: 43, Issue:9	Structure-activity relationships of novel heteroaryl-acrylonitriles as cytotoxic and antibacterial agents.
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID100625	Compound was tested for anticancer activities against L1210 leukemia in CD2F1 male mice at dose of 6.5 mg/kg per day; 0/6	1986	Journal of medicinal chemistry, Nov, Volume: 29, Issue:11	In the search for new anticancer drugs. 19. A predictive design of N,N:N',N':N'',N''-tri-1,2-ethanediylphosphorothioic triamide (TEPA) analogues.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID29763	partition coefficient with the use of 1-octanol / water solvent system	1986	Journal of medicinal chemistry, Jul, Volume: 29, Issue:7	In the search for new anticancer drugs. 17. Linear and cyclic polyether analogues of N,N:N',N':N'',N''-tri-1,2-ethanediylphosphoric triamide and N,N:N',N':N'',N''-tri-1,2-ethanediylphosphorothioic triamide.
AID364040	Cytotoxicity against human A427 cells after 96 hrs by microtiter assay	2008	European journal of medicinal chemistry, Sep, Volume: 43, Issue:9	Structure-activity relationships of novel heteroaryl-acrylonitriles as cytotoxic and antibacterial agents.
AID100488	Compound was tested for anticancer activities against L1210 leukemia in CD2F1 male mice at dose of 6.5 mg/kg per day	1986	Journal of medicinal chemistry, Nov, Volume: 29, Issue:11	In the search for new anticancer drugs. 19. A predictive design of N,N:N',N':N'',N''-tri-1,2-ethanediylphosphorothioic triamide (TEPA) analogues.
AID589242	Mechanism based inhibition of human cytochrome P450 2B6 measured by bupropion hydroxylation using human liver microsomes	2005	Current drug metabolism, Oct, Volume: 6, Issue:5	Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID588214	FDA HLAED, liver enzyme composite activity	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID120686	Compound was evaluated for the anticancer activity against P388 leukemia in CD2F1 male mice at a dose of 6 mg/kg/day.	1986	Journal of medicinal chemistry, Jul, Volume: 29, Issue:7	In the search for new anticancer drugs. 17. Linear and cyclic polyether analogues of N,N:N',N':N'',N''-tri-1,2-ethanediylphosphoric triamide and N,N:N',N':N'',N''-tri-1,2-ethanediylphosphorothioic triamide.
AID153206	Number of cures from P388 leukemia in CD2F1 male mice as tumor-free survivors after day 60.	1986	Journal of medicinal chemistry, Nov, Volume: 29, Issue:11	In the search for new anticancer drugs. 19. A predictive design of N,N:N',N':N'',N''-tri-1,2-ethanediylphosphorothioic triamide (TEPA) analogues.
AID977599	Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID425652	Total body clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID364031	Cytotoxicity against human 5637 cells after 96 hrs by microtiter assay	2008	European journal of medicinal chemistry, Sep, Volume: 43, Issue:9	Structure-activity relationships of novel heteroaryl-acrylonitriles as cytotoxic and antibacterial agents.
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID122077	Compound was evaluated for the anticancer activity against P388 leukemia in CD2F1 male mice at a dose of 5 mg/kg/after 30 days; 0/6	1986	Journal of medicinal chemistry, Jul, Volume: 29, Issue:7	In the search for new anticancer drugs. 17. Linear and cyclic polyether analogues of N,N:N',N':N'',N''-tri-1,2-ethanediylphosphoric triamide and N,N:N',N':N'',N''-tri-1,2-ethanediylphosphorothioic triamide.
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID364030	Cytotoxicity against human RT112 cells after 96 hrs by microtiter assay	2008	European journal of medicinal chemistry, Sep, Volume: 43, Issue:9	Structure-activity relationships of novel heteroaryl-acrylonitriles as cytotoxic and antibacterial agents.
AID588219	FDA HLAED, gamma-glutamyl transferase (GGT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID699541	Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1443980	Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch	2010	Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2	Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID131473	In vivo evaluation of percent increase in life span (ILS) against P388 lymphocytic leukemia in infected CD2F1 male mice and at 3 dose mg/kg	1984	Journal of medicinal chemistry, Jun, Volume: 27, Issue:6	In the search for new anticancer drugs. 9. Synthesis and anticancer activity of spin-labeled analogues of N,N:N',N':N",N"-Tri-1,2-ethanediylphosphoric triamide and N,N:N',N':N",N"-tri-1,2-ethanediylphosphorothioic triamide.
AID588215	FDA HLAED, alkaline phosphatase increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID139538	In vivo evaluation of test/control survival against P388 lymphocytic leukemia in CD2F1 male mice at dose 6 mg/kg; 22.2 / 9.2	1984	Journal of medicinal chemistry, Jun, Volume: 27, Issue:6	In the search for new anticancer drugs. 9. Synthesis and anticancer activity of spin-labeled analogues of N,N:N',N':N",N"-Tri-1,2-ethanediylphosphoric triamide and N,N:N',N':N",N"-tri-1,2-ethanediylphosphorothioic triamide.
AID364033	Cytotoxicity against human KYSE510 cells after 96 hrs by microtiter assay	2008	European journal of medicinal chemistry, Sep, Volume: 43, Issue:9	Structure-activity relationships of novel heteroaryl-acrylonitriles as cytotoxic and antibacterial agents.
AID364038	Cytotoxicity against human LCLC-103H cells after 96 hrs by microtiter assay	2008	European journal of medicinal chemistry, Sep, Volume: 43, Issue:9	Structure-activity relationships of novel heteroaryl-acrylonitriles as cytotoxic and antibacterial agents.
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID588216	FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1197742	Stimulation of human OATP1B1-mediated [3H]estrone 3-sulfate at 100 uM after 5 mins relative to control	2015	European journal of medicinal chemistry, Mar-06, Volume: 92	Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds.
AID23271	Partition coefficient (logD7.4)	1990	Journal of medicinal chemistry, Jul, Volume: 33, Issue:7	Structure-activity relationships of antineoplastic agents in multidrug resistance.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID364036	Cytotoxicity against human DAN-G cells after 96 hrs by microtiter assay	2008	European journal of medicinal chemistry, Sep, Volume: 43, Issue:9	Structure-activity relationships of novel heteroaryl-acrylonitriles as cytotoxic and antibacterial agents.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID153210	Antineoplastic activities against P388 leukemia in CD2F1 male mice.	1986	Journal of medicinal chemistry, Nov, Volume: 29, Issue:11	In the search for new anticancer drugs. 19. A predictive design of N,N:N',N':N'',N''-tri-1,2-ethanediylphosphorothioic triamide (TEPA) analogues.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID699539	Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID153212	Antineoplastic activity against P388 leukemia in CD2F1 male mice and the average percentage weight change on day 5 was measured.	1986	Journal of medicinal chemistry, Nov, Volume: 29, Issue:11	In the search for new anticancer drugs. 19. A predictive design of N,N:N',N':N'',N''-tri-1,2-ethanediylphosphorothioic triamide (TEPA) analogues.
AID364034	Cytotoxicity against human KYSE520 cells after 96 hrs by microtiter assay	2008	European journal of medicinal chemistry, Sep, Volume: 43, Issue:9	Structure-activity relationships of novel heteroaryl-acrylonitriles as cytotoxic and antibacterial agents.
AID589176	Mechanism based inhibition of rat cytochrome P450 2B1	2005	Current drug metabolism, Oct, Volume: 6, Issue:5	Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID235777	Therapeutic ratio as optimum dose/dose ILS40	1986	Journal of medicinal chemistry, Nov, Volume: 29, Issue:11	In the search for new anticancer drugs. 19. A predictive design of N,N:N',N':N'',N''-tri-1,2-ethanediylphosphorothioic triamide (TEPA) analogues.
AID364032	Cytotoxicity against human KYSE70 cells after 96 hrs by microtiter assay	2008	European journal of medicinal chemistry, Sep, Volume: 43, Issue:9	Structure-activity relationships of novel heteroaryl-acrylonitriles as cytotoxic and antibacterial agents.
AID409958	Inhibition of bovine brain MAOA	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID45400	Effect on cross resistance of CHO cells resistant to colchicine (CHRC5)	1990	Journal of medicinal chemistry, Jul, Volume: 33, Issue:7	Structure-activity relationships of antineoplastic agents in multidrug resistance.
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID589200	Mechanism based inhibition of rat cytochrome P450 2B1, partition ratio	2005	Current drug metabolism, Oct, Volume: 6, Issue:5	Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID117823	Net log cell kill is an estimate of the number of cells that are killed by the compound was calculated at dose of 10 mg/kg on days 1,5,9	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	Synthesis and antitumor evaluation of a highly potent cytotoxic DNA cross-linking polyamine analogue, 1,12-diaziridinyl-4,9-diazadodecane.
AID425653	Renal clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID364035	Cytotoxicity against human YAPC cells after 96 hrs by microtiter assay	2008	European journal of medicinal chemistry, Sep, Volume: 43, Issue:9	Structure-activity relationships of novel heteroaryl-acrylonitriles as cytotoxic and antibacterial agents.
AID153200	Antineoplastic activity against P388 leukemia in CD2F1 male mice and the percent increase in life span was measured on day 30.	1986	Journal of medicinal chemistry, Nov, Volume: 29, Issue:11	In the search for new anticancer drugs. 19. A predictive design of N,N:N',N':N'',N''-tri-1,2-ethanediylphosphorothioic triamide (TEPA) analogues.
AID364029	Cytotoxicity against human RT4 cells after 96 hrs by microtiter assay	2008	European journal of medicinal chemistry, Sep, Volume: 43, Issue:9	Structure-activity relationships of novel heteroaryl-acrylonitriles as cytotoxic and antibacterial agents.
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID115021	Percentage increase in life span when the compound was administered intraperitoneally at dose of 6 mg/Kg in P388 leukemia in CDF1 mice was determined	1986	Journal of medicinal chemistry, Jul, Volume: 29, Issue:7	In the search for new anticancer drugs. 17. Linear and cyclic polyether analogues of N,N:N',N':N'',N''-tri-1,2-ethanediylphosphoric triamide and N,N:N',N':N'',N''-tri-1,2-ethanediylphosphorothioic triamide.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID100469	Compound was tested for anticancer activities against L1210 leukemia in CD2F1 male mice at dose of 6.5 mg/kg per day	1986	Journal of medicinal chemistry, Nov, Volume: 29, Issue:11	In the search for new anticancer drugs. 19. A predictive design of N,N:N',N':N'',N''-tri-1,2-ethanediylphosphorothioic triamide (TEPA) analogues.
AID977602	Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID364037	Cytotoxicity against human SISO cells after 96 hrs by microtiter assay	2008	European journal of medicinal chemistry, Sep, Volume: 43, Issue:9	Structure-activity relationships of novel heteroaryl-acrylonitriles as cytotoxic and antibacterial agents.
AID153204	Lethal toxicity against P388 leukemia in CD2F1 male mice was determined	1986	Journal of medicinal chemistry, Nov, Volume: 29, Issue:11	In the search for new anticancer drugs. 19. A predictive design of N,N:N',N':N'',N''-tri-1,2-ethanediylphosphorothioic triamide (TEPA) analogues.
AID1449628	Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID589186	Mechanism based inhibition of human cytochrome P450 2B6, partition ratio	2005	Current drug metabolism, Oct, Volume: 6, Issue:5	Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID125596	In vivo evaluation of 30 day survival against P388 lymphocytic leukemia in CD2F1 male mice at dose mg/kg; out of 6 mice	1984	Journal of medicinal chemistry, Jun, Volume: 27, Issue:6	In the search for new anticancer drugs. 9. Synthesis and anticancer activity of spin-labeled analogues of N,N:N',N':N",N"-Tri-1,2-ethanediylphosphoric triamide and N,N:N',N':N",N"-tri-1,2-ethanediylphosphorothioic triamide.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID409960	Inhibition of bovine brain MAOB	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID153202	Compound was tested for its antineoplastic activities against P388 leukemia in CD2F1 male mice.	1986	Journal of medicinal chemistry, Nov, Volume: 29, Issue:11	In the search for new anticancer drugs. 19. A predictive design of N,N:N',N':N'',N''-tri-1,2-ethanediylphosphorothioic triamide (TEPA) analogues.
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID116814	Percent increase in life span was calculated by administering intravenously the compound dose of 10 mg/kg on days 1,5 and 9.	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	Synthesis and antitumor evaluation of a highly potent cytotoxic DNA cross-linking polyamine analogue, 1,12-diaziridinyl-4,9-diazadodecane.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID118516	In vivo antitumor studies were carried out on mice bearing L1210 murine leukemia cells, by administering intravenously the compound dose of 10 mg/kg on days 1,5 and 9.	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	Synthesis and antitumor evaluation of a highly potent cytotoxic DNA cross-linking polyamine analogue, 1,12-diaziridinyl-4,9-diazadodecane.
AID131476	In vivo evaluation of percent increase in life span (ILS) against P388 lymphocytic leukemia in infected CD2F1 male mice and at 6 dose mg/kg	1984	Journal of medicinal chemistry, Jun, Volume: 27, Issue:6	In the search for new anticancer drugs. 9. Synthesis and anticancer activity of spin-labeled analogues of N,N:N',N':N",N"-Tri-1,2-ethanediylphosphoric triamide and N,N:N',N':N",N"-tri-1,2-ethanediylphosphorothioic triamide.
AID699540	Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159550	Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening	2015	Nature cell biology, Nov, Volume: 17, Issue:11	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1609 (62.51)	18.7374
1990's	392 (15.23)	18.2507
2000's	270 (10.49)	29.6817
2010's	215 (8.35)	24.3611
2020's	88 (3.42)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	408 (14.28%)	5.53%
Reviews	168 (5.88%)	6.00%
Case Studies	145 (5.07%)	4.05%
Observational	3 (0.10%)	0.25%
Other	2,134 (74.67%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (219)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase I/II Dose Escalation Trial of Clofarabine, in Addition to Melphalan and Thiotepa as Myeloablative Regimen Followed by an Allogeneic Unmodified Hematopoietic Stem Cell Transplant From HLA-Compatible Related or Unrelated Donors for the Treatment of [NCT00423514]	Phase 1/Phase 2	38 participants (Actual)	Interventional	2006-11-20	Completed
A Phase II Study to Evaluate the Safety and Efficacy of IV Busulfan, Melphalan, and Thiotepa (BuMelTT) Followed By Autologous PBSC Infusion for Patients With Hodgkin's Disease and Non-Hodgkin's Lymphoma [NCT00238433]	Phase 2	37 participants (Actual)	Interventional	2005-03-31	Completed
A Phase I/II Pilot Study of Memory-like NK Cells to Consolidate TCRαβ T Cell Depleted Haploidentical Transplant in High-risk AML [NCT06158828]	Phase 1/Phase 2	48 participants (Anticipated)	Interventional	2024-03-31	Not yet recruiting
A Feasibility Study of Vorinostat (SAHA) Combined With Isotretinoin and Chemotherapy in Infants With Embryonal Tumors of the Central Nervous System [NCT00867178]	Phase 1	33 participants (Actual)	Interventional	2009-02-25	Completed
Allogeneic Hematopoietic Cell Transplantation for Patients With Non-Malignant Disorders Using Treosulfan, Fludarabine, and Thiotepa [NCT03980769]	Phase 2	40 participants (Anticipated)	Interventional	2021-05-05	Recruiting
A Phase II Trial of Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated Donors [NCT03615144]	Phase 2	1 participants (Actual)	Interventional	2018-07-23	Terminated(stopped due to Participant accrual low and the study was closed)
Reduced Intensity Related Donor Peripheral Blood Derived Hematopoietic Progenitor Cell Transplantation for Patients With Severe Sickle Cell Disease [NCT04362293]	Phase 2	40 participants (Anticipated)	Interventional	2020-04-30	Suspended(stopped due to We are holding enrollment, due to some recent SAEs.)
Multi-center, Phase II Study to Assess the Safety and Efficacy of Haploidentical Bone Marrow Transplantation Using Reduced Intensity Conditioning(RIC)Regimen and Post-transplant Cyclophosphamide,in Patients With Poor Prognosis Lymphomas [NCT02049580]	Phase 2	47 participants (Anticipated)	Interventional	2013-07-31	Recruiting
TEAM (Thiotepa, Etoposide, Cytosar, Melphalan ) in Preparation for Autologous Hematopoietic Stem-Cell Transplantation in Patients With Non-Hodgkin's and Hodgkin's Lymphoma. [NCT03346096]	Phase 2	50 participants (Anticipated)	Interventional	2018-10-09	Active, not recruiting
[NCT01342237]	Phase 2	33 participants (Anticipated)	Interventional	2011-03-31	Recruiting
CD34+ Stem Cell Selection for Patients Receiving a Matched or Partially Matched Family or Unrelated Adult Donor Allogeneic Stem Cell Transplant for Malignant Disease [NCT02061800]	Phase 1/Phase 2	15 participants (Anticipated)	Interventional	2013-06-03	Recruiting
Modified TBF Regimen as Conditioning Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma：Phase II Study [NCT05598593]	Phase 2	70 participants (Anticipated)	Interventional	2022-10-23	Recruiting
HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies [NCT00145626]	Phase 2	40 participants (Actual)	Interventional	2004-05-31	Completed
Randomized Trial of Unmanipulated Versus Expanded Cord Blood [NCT00067002]	Phase 2	110 participants (Actual)	Interventional	2003-04-30	Completed
A Randomized Trial of Sirolimus-Based Graft Versus Host Disease Prophylaxis After Hematopoietic Stem Cell Transplantation in Relapsed Acute Lymphoblastic Leukemia [NCT00382109]	Phase 3	146 participants (Actual)	Interventional	2007-03-31	Completed
A Single-arm, Prospective, Multicenter Clinical Trial of the Combination of Thiotepa and Pomalidomide for the Treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma. [NCT05931328]	Phase 2	28 participants (Anticipated)	Interventional	2022-10-15	Recruiting
Transplantation of Umbilical Cord Blood for Patients With Hematological Diseases With Cyclophosphamide/Fludarabine/Total Body Irradiation or Cyclophosphamide/Fludarabine/Thiotepa/Total Body Irradiation Myeloablative Preparative Regimen [NCT00719888]	Phase 2	135 participants (Actual)	Interventional	2005-11-18	Active, not recruiting
A Phase II Trial of CD34+ Enriched Transplants From HLA-Compatible Related or Unrelated Donors for Treatment of Patients With Hematologic Malignancies [NCT04282174]	Phase 2	0 participants (Actual)	Interventional	2022-09-30	Withdrawn(stopped due to Study was split into two new studies before the first participant was enrolled.)
Peripheral Stem Cell Transplantation Protocol for Patients With Previously Treated Advanced Breast Cancer - A Phase II Pilot Study [NCT00004172]	Phase 2	0 participants	Interventional	1999-10-31	Completed
Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors [NCT00432094]	Phase 2	23 participants (Actual)	Interventional	2006-12-19	Completed
Safety and Efficacy of Orelabrutinib（O） in Combination With Thiotepa（T） in Refractory and Relapsed Primary CNS Lymphoma： A Single-arm, Multicenter Phase Ib/II Study（OT） [NCT05021770]	Phase 1/Phase 2	29 participants (Anticipated)	Interventional	2021-12-31	Not yet recruiting
A Phase II Trial for Patients With Inflammatory (Stage IIIB) and Responsive Metastatic Stage IV Breast Cancer Using Busulfan, Melphalan and Thiotepa Followed by Autologous or Syngeneic PBSC Rescue and 12 Weeks of Post-Engraftment Immunotherapy With Low-Do [NCT00003199]	Phase 2	50 participants (Actual)	Interventional	1997-11-30	Completed
A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) Versus HLA-Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) With Acute Leukemia or Myelodysplastic [NCT05457556]	Phase 3	435 participants (Anticipated)	Interventional	2023-03-15	Recruiting
Itacitinib to Prevent Graft Versus Host Disease [NCT04859946]	Phase 1	30 participants (Anticipated)	Interventional	2022-01-11	Recruiting
A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular &Amp; Spinal Canal Irradiation (WVSCI) for Patients With Localized Non-Germinomatous Central Nervous System Germ Cell Tumor [NCT04684368]	Phase 2	160 participants (Anticipated)	Interventional	2021-07-13	Recruiting
Partially HLA-Mismatched Related Donor Hematopoietic Stem Cell Transplantation Using Killer Immunoglobulin Receptor and Human Leukocyte Antigen Based Donor Selection [NCT02880293]		44 participants (Actual)	Interventional	2016-08-23	Completed
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL) [NCT03126916]	Phase 3	724 participants (Anticipated)	Interventional	2018-05-14	Active, not recruiting
A Phase II Trial of Allogeneic Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Antifungal Prophylaxis With Posaconazole. [NCT03434704]	Phase 2	10 participants (Actual)	Interventional	2018-06-18	Completed
Phase I Study of Valproic Acid Expanded Cord Blood Stem Cells as an Allogeneic Donor Source for Adults With Hematological Malignancies [NCT03885947]	Phase 1	7 participants (Actual)	Interventional	2019-02-21	Completed
Clinical Research of Allogeneic Hematopoietic Stem Cell Transplantation for Treatment of Children With Stage 4/M Neuroblastoma: A Prospective, Single-arm, Phase II, Multi-center Trial [NCT05303727]	Phase 2	64 participants (Anticipated)	Interventional	2022-08-31	Not yet recruiting
An International Phase II Trial Assessing Tolerability and Efficacy of Sequential Methotrexate-Aracytin-based Combination and R-ICE Combination, Followed by HD Chemotherapy Supported by ASCT, in Patients With Systemic B-cell Lymphoma With CNS Involvement [NCT02329080]	Phase 2	76 participants (Actual)	Interventional	2014-12-31	Active, not recruiting
A Phase 2, Open-Label Study to Evaluate the Efficacy and Safety of Patient-Specific Immunotherapy, Recombinant Idiotype Conjugated to KLH (Id-KLH) and Administered With GM-CSF, in Patients With CNS Lymphoma [NCT00621036]	Phase 2	0 participants (Actual)	Interventional	2007-10-19	Withdrawn(stopped due to MyVax did not meet its primary endpoints)
Tandem Myeloablative Consolidation Therapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma [NCT02605421]	Phase 2	12 participants (Anticipated)	Interventional	2016-06-30	Recruiting
Reduced-dose Radiotherapy Following High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Central Nervous System Non-germinomatous Germ Cell Tumors [NCT02784054]	Phase 2	25 participants (Anticipated)	Interventional	2014-04-30	Recruiting
A Phase II Pediatric Study of a Graft-VS.-Host Disease (GVHD) Prophylaxis Regimen With no Calcineurin Inhibitors After Day +60 Post First Allogeneic Hematopoietic Cell Transplant for Hematological Malignancies [NCT05579769]	Phase 2	32 participants (Anticipated)	Interventional	2022-11-04	Recruiting
T-Cell Depleted, Alternative Donor Transplant in Pediatric and Adult Patients With Severe Sickle Cell Disease (SCD) and Other Transfusion-Dependent Anemias [NCT03653338]	Phase 1/Phase 2	5 participants (Anticipated)	Interventional	2018-08-02	Recruiting
A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma [NCT06172296]	Phase 3	478 participants (Anticipated)	Interventional	2024-02-14	Not yet recruiting
A Phase I/II Open-Label Study of ECT-001-Expanded Cord Blood Transplantation in Pediatric and Young Adult (<21year) Patients With High-Risk and Very High-Risk Myeloid Malignancies [NCT04990323]	Phase 1/Phase 2	12 participants (Anticipated)	Interventional	2021-12-01	Recruiting
A Phase II Randomized Controlled Trial Comparing GVHD-Reduction Strategies for Allogeneic Peripheral Blood Transplantation (PBSCT) for Patients With Acute Leukemia or Myelodysplastic Syndrome: Selective Depletion of CD45RA+ Naïve T Cells (TND) vs. Post-Tr [NCT03970096]	Phase 2	120 participants (Anticipated)	Interventional	2019-11-19	Recruiting
A Reduced Intensity Conditioning Regimen With CD3-Depleted Hematopoietic Stem Cells to Improve Survival for Patients With Hematologic Malignancies Undergoing Haploidentical Stem Cell Transplantation [NCT00566696]	Phase 2	73 participants (Actual)	Interventional	2007-12-14	Completed
Therapy-Optimization Trial and Phase II Study for the Treatment of Relapsed or Refractory of Primitive Neuroectodermal Brain Tumors and Ependymomas in Children and Adolescents [NCT00749723]	Phase 2/Phase 3	174 participants (Actual)	Interventional	2006-02-01	Completed
CD34+Stem Cell Selection for Patients Receiving Partially Matched Family or Matched Unrelated Adult Donor Allogeneic Stem Cell Transplantations for Malignant and Non-Malignant Disease [NCT01049854]	Phase 2	20 participants (Actual)	Interventional	2011-09-30	Completed
Lung Transplant in Tandem With Bone Marrow Transplant for Combined Lung and Bone Marrow Failure [NCT03500731]	Phase 1/Phase 2	8 participants (Anticipated)	Interventional	2018-04-19	Recruiting
Allogeneic Hematopoietic Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors [NCT03615105]	Phase 2	9 participants (Actual)	Interventional	2018-07-25	Active, not recruiting
Freiburg ZNS-NHL Study: Therapy for Patients With Primary Non-Hodgkin Lymphoma of the CNS - Sequential High Dosage Chemotherapy With Autologous Peripheral Blood Stem Cell Plantation [NCT00647049]	Phase 2	78 participants (Anticipated)	Interventional	2007-01-31	Recruiting
A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors [NCT02653196]	Early Phase 1	1 participants (Actual)	Interventional	2015-09-30	Terminated(stopped due to The Principal Investigator left the institution.)
Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies [NCT00824135]	Phase 1	34 participants (Actual)	Interventional	2009-01-31	Completed
Optimized Cord Blood Transplantation for the Treatment of High-Risk Hematologic Malignancies in Adults and Pediatrics [NCT06013423]	Phase 2	54 participants (Anticipated)	Interventional	2024-02-06	Not yet recruiting
Clofarabine Based Remission Induction Followed by Haploidentical Stem Cell Transplantation in Children With Refractory Hematological Malignancies [NCT01025778]	Phase 2	7 participants (Actual)	Interventional	2009-12-31	Completed
Infusion of Expanded Cord Blood T Cells Following Cord Blood Transplantation [NCT00972101]	Phase 1	0 participants (Actual)	Interventional	2009-09-30	Withdrawn(stopped due to Development of other studies led to termination without recruitment.)
Randomized Phase II Trial On Primary Chemotherapy With High-Dose Methotrexate And High-Dose Cytarabine With Or Without Thiotepa, And With Or Without Rituximab, Followed By Brain Irradiation Vs. High-Dose Chemotherapy Supported By Autologous Stem Cells Tra [NCT01011920]	Phase 2	126 participants (Actual)	Interventional	2009-11-30	Completed
Three-arm Clinical Trial for Patients With Hematologic Malignancies and Mismatched Donors - Haploidentical, 1 Antigen Mismatch Related or Unrelated, and Matched Unrelated Donor (MUD)- Using a T-cell Replete Allograft and High-dose Post-transplant Cyclopho [NCT01010217]	Phase 2	176 participants (Actual)	Interventional	2009-11-05	Completed
High-dose MIBG With Subsequent Transplantation of Haploidentical Stem Cells in Children With Therapy Resistant Neuroblastoma [NCT00790413]	Early Phase 1	15 participants (Anticipated)	Interventional	2005-08-31	Active, not recruiting
A Phase II Trial of Transplants From HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies and Other Lethal H [NCT01119066]	Phase 2	422 participants (Actual)	Interventional	2010-05-03	Completed
A Trial of Intensive Multi-Modality Therapy for Extra-Ocular Retinoblastoma [NCT00554788]	Phase 3	60 participants (Actual)	Interventional	2008-02-04	Active, not recruiting
Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies [NCT00857389]	Phase 2	60 participants (Actual)	Interventional	2009-03-02	Completed
A Pilot Study of Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed CNS Involvement by Lymphoma [NCT02724904]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2017-05-31	Withdrawn(stopped due to Drug logistics)
A Pilot Induction Regimen Incorporating Chimeric 14.18 Antibody (ch14.18, Dinutuximab) (NSC# 764038) and Sargramostim (GM-CSF) for the Treatment of Newly Diagnosed High-Risk Neuroblastoma [NCT03786783]	Phase 2	42 participants (Actual)	Interventional	2019-01-14	Active, not recruiting
[NCT00936156]	Phase 2	68 participants (Actual)	Interventional	2009-01-31	Completed
CAMP 004A - Phase 2 Study Of Intensive Chemotherapy (BET) For Selected Categories Of Malignant Central Nervous System Tumor [NCT00007982]	Phase 2	30 participants (Anticipated)	Interventional	1999-04-30	Completed
A Phase II Trial of Haplotype Mismatched Hematopoietic Stem Cell Transplantation Using Highly Purified CD34 Cells in Patients With Hematological Malignancies [NCT00593554]	Phase 2	9 participants (Actual)	Interventional	2007-08-07	Terminated(stopped due to Slow accrual)
Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma [NCT00567567]	Phase 3	665 participants (Actual)	Interventional	2007-11-05	Completed
A Multi-center Phase II Study of Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD [NCT00914940]	Phase 2	41 participants (Actual)	Interventional	2009-12-17	Terminated(stopped due to Did not reach one of the primary endpoints of decreased total acute GVHD)
Pilot Study of Unrelated Cord Blood Transplantation in Patients With Poor Risk Haematological Malignancies [NCT00916045]	Phase 2	40 participants (Anticipated)	Interventional	2009-09-30	Terminated(stopped due to Recruitment issues)
Phase I / II Study of Sequential High-dose Chemotherapy With Stem Cell Support in Children Younger Than 5 Years of Age With High-risk Medulloblastoma [NCT02025881]	Phase 1/Phase 2	29 participants (Actual)	Interventional	2013-09-14	Active, not recruiting
Autotransplantation and Her 2 Neu Antibody Immunotherapy in Advanced Breast Cancer [NCT00006123]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2000-07-31	Withdrawn(stopped due to Never started)
CAMP 013:- Tandem Thiotepa Regimen For Selected Malignant Gliomas:1) Primary Or Recurrent Glioblastoma Multiforme (GBM); and 2) Recurrent Anaplastic Astrocytomas (AA), Oligodendrogliomas (O), Oligoastrocytomas (OA), Ependymomas And Primitive Neuroectoderm [NCT00008008]	Phase 2	40 participants (Anticipated)	Interventional	1997-09-30	Completed
High-Dose Chemotherapy Followed By Autologous Hematopoietic Stem Cell Support And One Of Two Regimens Aimed At Modifying Immune Reconstitution In Women With High Risk Stage 2 And Stage 3 Breast Cancer [NCT00008203]	Phase 3	0 participants	Interventional	1996-05-31	Completed
Prospective , Multicentric, Randomized Phase II Study, Evaluating the Role of Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue After Conventional Chemotherapy for Primary Central Nervous System in Young Patients (< 60 y) [NCT00863460]	Phase 2	140 participants (Actual)	Interventional	2008-10-03	Active, not recruiting
A Pilot Study Of Tandem High Dose Chemotherapy With Stem Cell Rescue Following Induction Therapy In Children With High Risk Neuroblastoma [NCT00017368]	Phase 2	42 participants (Actual)	Interventional	2001-04-30	Completed
Efficacy and Tolerance Adjuvant High-Dose Thiotepa With Peripheral Stem Cell Rescue Associated With Conventional Chemotherapy in Children and Adults With Relapsed Osteosarcoma [NCT00978471]	Phase 2	44 participants (Actual)	Interventional	2009-07-31	Completed
Haploidentical Hematopoietic Stem Cell Transplantation for Pediatric Patients With Wiskott-Aldrich Syndrome: A Pilot Study [NCT00160355]	Phase 1	4 participants (Actual)	Interventional	2005-05-31	Completed
Phase II Study of Purging of Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer Patients [NCT00429182]	Phase 2	32 participants (Actual)	Interventional	2007-06-30	Completed
A Phase II Trial of a Chemotherapy Based Regimen of Intravenous Busulfan (Busulfex), Melphalan and Thiotepa as Myeloablative Regimen Followed by a T- Cell Depleted Allogeneic Hematopoietic Stem Cell Transplant From and HLA-Compatible Donor in the Treatmen [NCT00357396]	Phase 2	10 participants (Actual)	Interventional	2005-06-30	Completed
High-dose Chemotherapy and Autologous Stem Cell Transplant or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma - Randomized Phase III Trial [NCT02531841]	Phase 3	250 participants (Anticipated)	Interventional	2014-07-31	Recruiting
Timed Sequential Busulfan and Post Transplant Cyclophosphamide for Allogeneic Transplantation [NCT02861417]	Phase 2	204 participants (Actual)	Interventional	2016-08-05	Active, not recruiting
A Phase II Study To Assess The Ability Of Neoadjuvant Chemotherapy Plus/Minus Second Look Surgery To Eliminate All Measurable Disease Prior To Radiotherapy For NGGCT [NCT00047320]	Phase 2	104 participants (Actual)	Interventional	2004-01-31	Completed
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies [NCT03849651]	Phase 2	140 participants (Anticipated)	Interventional	2019-01-31	Recruiting
A Phase II Study of Reduced Intensity Conditioning in Pediatric Patients and Young Adults ≤55 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood, Bone Marrow, or Peripheral Blood Stem Cell Transplantation [NCT01962415]	Phase 2	100 participants (Anticipated)	Interventional	2014-02-04	Recruiting
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia [NCT01949129]	Phase 2/Phase 3	1,000 participants (Anticipated)	Interventional	2013-04-30	Recruiting
HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation With Randomization to Either Single Cycle or [NCT02875314]	Phase 4	250 participants (Anticipated)	Interventional	2015-09-30	Recruiting
A Reduced Intensity Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies. [NCT00739141]	Phase 2	86 participants (Actual)	Interventional	2008-08-12	Completed
Population Pharmacokinetics and Pharmacodynamics of Thiotepa and TEPA in Pediatric Patients Undergoing Hematopoietic Cell Transplantation (HCT). [NCT03609840]		25 participants (Actual)	Observational	2017-05-24	Completed
Transplantation Using Reduced Intensity Approach for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone Marrow [NCT02757885]	Phase 2	10 participants (Actual)	Interventional	2019-07-10	Completed
Multi-Center Phase II Randomized Controlled Trial of Naïve T Cell Depletion for Prevention of Chronic Graft-Versus-Host Disease in Children and Young Adults [NCT03779854]	Phase 2	68 participants (Anticipated)	Interventional	2019-08-29	Recruiting
Autologous Stem Cell Transplantation With CD34-Selected Peripheral Blood Stem Cells (PBSC) in Patients With Treatment Resistant Systemic Sclerosis (SSc) [NCT03630211]	Phase 2	8 participants (Anticipated)	Interventional	2018-07-31	Recruiting
Tandem High-dose Chemotherapy and Autologous Stem Cell Rescue in Patients With High-risk Neuroblastoma [NCT00793845]	Phase 2	40 participants (Anticipated)	Interventional	2008-08-31	Completed
Abatacept for Graft Versus Host Disease Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease: a Sickle Transplant Alliance for Research Trial [NCT02867800]	Phase 1	24 participants (Actual)	Interventional	2016-07-31	Active, not recruiting
Allogeneic Stem Cell Transplantation for Children and Adolescents With CML: Conditioning Regimen, Donor Selection, Supportive Care and Diagnostic Procedures [NCT02707393]	Phase 2/Phase 3	13 participants (Actual)	Interventional	2009-04-30	Completed
High Dose Thiotepa and Melphalan With Autologous Hematopoietic Stem Cell Transplant in Children and Adolescents With Solid Tumors [NCT00607984]		20 participants (Anticipated)	Interventional	2006-06-30	Recruiting
Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia [NCT01423500]	Phase 3	405 participants (Anticipated)	Interventional	2007-01-31	Active, not recruiting
Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia [NCT01423747]	Phase 3	400 participants (Anticipated)	Interventional	2003-07-31	Active, not recruiting
Randomized Phase II/III Study of Individualized Neoadjuvant Chemotherapy in ' Triple Negative' Breast Tumors [NCT01057069]	Phase 2/Phase 3	310 participants (Actual)	Interventional	2010-01-31	Active, not recruiting
Multicenter Phase I/II Study of Haploidentical Hematopoietic Cell Transplantation With CD3/CD19 Depleted Grafts in Patients With Treatment Refractory Hematologic Malignancies [NCT00202917]	Phase 1/Phase 2	61 participants (Actual)	Interventional	2004-02-29	Completed
Response-based Treatment for Children With Unresectable Localized Soft Tissue Sarcomas [NCT02784015]	Phase 2	41 participants (Anticipated)	Interventional	2016-05-31	Recruiting
Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients With Symptomatic Sickle Cell Disease. (BMTCTN1507) [NCT03263559]	Phase 2	80 participants (Anticipated)	Interventional	2017-10-03	Active, not recruiting
Treatment Protocol for High-Risk PNET Brain Tumors in Children With Surgery, Sequential Chemotherapy, Conventional and High-Dose With Peripheral Blood Stem Cell Transplantation and Radiation Therapy [NCT00180791]	Phase 2	71 participants (Anticipated)	Interventional	2002-07-31	Recruiting
Thiotepa Incorporating TBI/Cy Conditioning Regimen Followed by HSCT for EBV-HLH With Central Nervous System Involvement: a Prospective Single-arm Clinical Study [NCT05854225]		20 participants (Anticipated)	Interventional	2022-01-01	Recruiting
Transplantation of Haploidentical CD34+ Purified Peripheral Blood Stem Cells With NK-Cell Add-Back Following Conditioning With Total Body Irradiation, Thiotepa, Fludarabine and OKT3 [NCT00450983]	Phase 2	1 participants (Actual)	Interventional	2006-12-31	Terminated
A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies Using Melphalan for T-Cell Tolerization [NCT01350258]	Phase 1/Phase 2	8 participants (Actual)	Interventional	2011-04-30	Terminated(stopped due to Poor accrual)
Dose Escalation of Total Marrow Irradiation Added to an Alkylator-Intense Conditioning Regimen for Patients With High Risk or Relapsed Solid Tumors [NCT00623077]	Phase 1	23 participants (Actual)	Interventional	2005-08-31	Terminated(stopped due to Replaced by another study)
Phase 2 Study of Personalized r-ATG Dosing to Improve Survival Through Enhanced Immune Reconstitution in Pediatric and Adult Patients Undergoing Ex-vivo CD34-Selected Allogeneic-HCT (PRAISE-IR) [NCT04872595]	Phase 2	56 participants (Anticipated)	Interventional	2021-04-30	Recruiting
A PILOT TRIAL OF INTERLEUKIN-2 WITH G-CSF AS PRIMING THERAPY FOR PERIPHERAL BLOOD STEM CELL HARVESTING IN PATIENTS WITH ADVANCED BREAST CANCER: STAMP V HIGH DOSE CHEMOTHERAPY, STEM CELL INFUSION AND POST-INFUSION G-CSF AND INTERLEUKIN-2 [NCT00002616]	Phase 1	36 participants (Anticipated)	Interventional	1995-02-28	Active, not recruiting
A Phase II Trial of T-Cell Depleted Marrow Grafts Combined With Infusions of G-CSF Stimulated, CD34 Ceprate Stem Cell Column Selected, E-Rosette Depleted Peripheral Blood Progenitor Cells Derived From HLA Haplotype Matched Related Donors for Patients With [NCT00002718]	Phase 2	31 participants (Actual)	Interventional	1995-11-30	Completed
A Comparison of Intensive Sequential Chemotherapy Using Doxorubicin Plus Paclitaxel Plus Cyclophosphamide With High Dose Chemotherapy and Autologous Hematopoietic Progenitor Cell Support for Primary Breast Cancer in Women With 4-9 Involved Axillary Lymph [NCT00002772]	Phase 3	602 participants (Actual)	Interventional	1996-07-31	Terminated(stopped due to poor accrual)
Treatment of High Risk Central Nervous System Embryonal Tumors With Conventional Radiotherapy and Intensive Consolidation Chemotherapy With Peripheral Blood Progenitor Cell (PBSC) Support [NCT00003846]	Phase 2	25 participants (Actual)	Interventional	1999-07-31	Completed
Phase II Study of Intensive Chemotherapy With Autologous Peripheral Blood Stem Cell Support in Patients With Cisplatin Resistant Germ Cell Tumors [NCT00003852]	Phase 2	45 participants (Anticipated)	Interventional	1998-03-31	Terminated(stopped due to lack of patient inclusion)
A Phase III Study of High-Dose Chemotherapy Using Busulfan, Melphalan and Thiotepa Versus Cyclophosphamide,Thiotepa, Carboplatin Followed by Autologous Stem Cell Transplantation in Patients With High-Risk Primary Stage II or III (Non-Inflammatory) Breast [NCT00003972]	Phase 3	280 participants (Anticipated)	Interventional	1998-07-31	Completed
Reduced Intensity Conditioning Regimen for Haplo-identical Family Donor Stem Cell Transplants for Hematologic Malignancies With Delayed Add-back of Non-alloreactive T Cells [NCT00104975]	Phase 1	20 participants (Anticipated)	Interventional	2005-02-28	Completed
A Phase I Dose Escalation Trial of Clofarabine in Addition to Topotecan, Vinorelbine, Thiotepa, and Dexamethasone in Pediatric Patients With Relapsed or Refractory Acute Leukemia [NCT00462787]	Phase 1	23 participants (Actual)	Interventional	2007-04-30	Completed
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS [NCT04708054]	Phase 2	100 participants (Anticipated)	Interventional	2021-10-21	Recruiting
CD34 Selected Allogeneic Hematopoietic Cell Transplantation With Myeloablative Conditioning and CD8+ Memory T Cell Infusion For Patients With Myelodysplastic Syndrome, Acute Leukemia, and Chronic Myelogenous Leukemia [NCT04151706]	Phase 2	20 participants (Anticipated)	Interventional	2020-02-27	Suspended(stopped due to Interim analysis)
Combined Haploidentical-Cord Blood Transplantation for Adults and Children [NCT00943800]		87 participants (Actual)	Interventional	2006-10-09	Completed
Treatment of Atypical Teratoid/Rhabdoid Tumors (AT/RT) of the Central Nervous System With Surgery, Intensive Chemotherapy, and 3-D Conformal Radiation [NCT00653068]	Phase 3	70 participants (Actual)	Interventional	2008-12-08	Active, not recruiting
Randomized Phase II/III Study of Intensified Alkylating Agent Chemotherapy With Peripheral Blood Progenitor Cell Support in the Preoperative Chemotherapy of Breast Tumors That Are Deficient for Homologous Recombination. [NCT00448266]	Phase 2/Phase 3	12 participants (Actual)	Interventional	2007-05-31	Terminated(stopped due to Activation of a similar multicenter study for same population)
A Feasibility Trial of Post-Transplant Infusion of Allogeneic Regulatory T Cells and Allogeneic Conventional T Cells in Patients With Hematologic Malignancies Undergoing Allogeneic Myeloablative Hematopoietic Cell Transplantation From Haploidentical-Relat [NCT01050764]	Phase 1/Phase 2	10 participants (Actual)	Interventional	2009-06-30	Terminated(stopped due to Safety)
A Randomized Phase II Trial of Myeloablative Versus Non-Myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-cell Lymphoma [NCT01511562]	Phase 2	113 participants (Actual)	Interventional	2012-09-30	Active, not recruiting
An International Multicenter Phase II Randomised Trial Evaluating and Comparing Two Intensification Treatment Strategies for Metastatic Neuroblastoma Patients With a Poor Response to Induction Chemotherapy [NCT03165292]	Phase 2	34 participants (Actual)	Interventional	2018-10-01	Terminated(stopped due to The Sponsor has been notified of an interruption in the international supply, and there is a possibility that 131I-mlBG would be unavailable to patients randomised to arm A of the trial)
A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children < 36 Months Old With Intensive Induction Chemotherapy With Methotrexate Followed by Consolidation With Stem Cell Rescue vs. [NCT00336024]	Phase 3	91 participants (Actual)	Interventional	2007-08-06	Active, not recruiting
A RANDOMIZED TRIAL OF UNMODIFIED VERSUS T-CELL DEPLETED ALLOGENEIC HLA-IDENTICAL BONE MARROW TRANSPLANTATION FOR THE TREATMENT OF ACUTE LEUKEMIAS [NCT00002534]	Phase 3	0 participants	Interventional	1993-05-31	Completed
Phase II Study of Haploidentical Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With High-Risk Acute Myeloid Leukemia in First Remission [NCT00101140]	Phase 2	0 participants (Actual)	Interventional		Withdrawn
A Phase I/II Study of Total Body Irradiation, Thiotepa, and Fludarabine as Conditioning for Haploidentical CD34+ Purified Peripheral Blood Stem Cell Transplants [NCT00112567]	Phase 1/Phase 2	20 participants (Anticipated)	Interventional	2003-04-30	Completed
Clinical Correlative Studies In Primary Central Nervous System Germ Cell Tumors: The Third International CNS Germ Cell Tumor Study Group Protocol [NCT00025324]	Phase 2	0 participants	Interventional	2000-12-31	Active, not recruiting
Dose Escalation of Temozolomide in Combination With Thiotepa and Carboplatin With Autologous Stem Cell Rescue in Patients With Malignant Brain Tumors With Minimal Residual Disease [NCT00025558]	Phase 1	0 participants	Interventional	2000-10-31	Completed
A Phase II Study Of Mobilization Chemotherapy With GMCSF And GCSF Followed By High Dose Therapy Combined With IL2 Activated Autologous Peripheral Blood Stem Cells Followed By Sequential IL2 Therapy As Treatment For Solid Tumors And Lymphoma [NCT00027937]	Phase 2	0 participants	Interventional	2001-08-31	Completed
A Phase III Randomized Trial for the Treatment of Pediatric High Grade Gliomas at First Recurrence With a Single High Dose Chemotherapy and Autologous Stem Cell Transplant Versus Three Courses of Intermediate Dose Chemotherapy With Peripheral Blood Stem C [NCT00078988]	Phase 3	1 participants (Actual)	Interventional	2004-10-31	Completed
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotep [NCT00392886]	Phase 3	120 participants (Anticipated)	Interventional	2004-03-31	Active, not recruiting
High-dose Alkylating Chemotherapy in Oligo-metastatic Breast Cancer Harboring Homologous Recombination Deficiency [NCT01646034]	Phase 3	74 participants (Actual)	Interventional	2014-09-30	Active, not recruiting
Multi-Cycle High-Dose Chemotherapy Versus Optimized Conventionally-Dosed Chemotherapy in Patients With Metastatic Breast Cancer: A Phase II Prospective Randomized Trial [NCT00012311]	Phase 2	0 participants	Interventional	2000-01-31	Active, not recruiting
Treatment Of Recurrent Central Nervous System Primitive Neuroectodermal Tumors (PNETs) In Children And Adolescents A Strategy Including The Use Of High Dose Thiotepa And High Dose Carboplatin [NCT00025077]	Phase 2	50 participants (Anticipated)	Interventional	2000-01-31	Completed
N8: Dose-Intensive Chemotherapy Plus Biologics in the Treatment of Neuroblastoma [NCT00040872]	Phase 2	0 participants	Interventional	2000-06-30	Completed
Phase II Trial of T-Cell Depleted Hematopoietic Stem Cell Transplants (SBA-E-BM) From HLA Compatible Related or Unrelated Donors After a Myeloablative Preparative Regimen of Hyperfractionated TBI, Thiotepa and Cyclophosphamide (TBI/Thio/cy) for Treatment [NCT00028730]	Phase 2	25 participants (Actual)	Interventional	2001-08-31	Completed
Autologous Blood and Marrow Transplantation for Hematologic Malignancy and Selected Solid Tumors [NCT00060255]	Phase 2	451 participants (Actual)	Interventional	1991-12-31	Completed
A Phase III Randomized Comparison of High Dose Chemotherapy G-CSF To G-CSF For Mobilization of Peripheral Blood Stem Cells For Autologous Transplantation For Patients With Responsive Metastatic Breast Cancer Or High Risk Stage II-III Patients [NCT00002836]	Phase 3	184 participants (Actual)	Interventional	1995-09-26	Completed
Pilot Study Of T-Cell-Depleted Peripheral Blood Stem Cell Transplantation From Partially Matched Related Donors For Patients With High-Risk Leukemia [NCT00066417]	Phase 2	51 participants (Anticipated)	Interventional		Terminated(stopped due to Trial was withdrawn for drug availability issues.)
A Phase II Study of Methotrexate and Thiotepa Chemotherapy for Patients With Newly Diagnosed Primary CNS Lymphoma [NCT00045539]	Phase 2	0 participants	Interventional	2002-10-31	Completed
Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated [NCT02870907]	Phase 2	185 participants (Anticipated)	Interventional	2010-03-31	Recruiting
An Out Patient Dose Escalation Trial of High Dose Mitoxantrone, Thiotepa and Cyclophosphamide Plus Autologous Blood Cell Rescue and Amifostine Cytoprotection [NCT00003068]	Phase 2	30 participants (Anticipated)	Interventional	1997-06-30	Completed
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) [NCT04221035]	Phase 3	800 participants (Anticipated)	Interventional	2019-11-05	Recruiting
Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma (PCNSL) [NCT00596154]	Phase 2	33 participants (Actual)	Interventional	2004-12-31	Completed
A Study of Hematopoietic Stem Cell Transplantation (HSCT) in Immune Function Disorders Using a Reduced Intensity Preparatory Regime [NCT01821781]	Phase 2	20 participants (Anticipated)	Interventional	2013-03-31	Recruiting
A Multicenter, Prospective Trial to Evaluate the Role of NK Cell KIR Epitope Mismatch on Mortality and Disease Relapse in T-Cell Depleted Hematopoietic Stem Cell Transplantation From HLA-C Mismatched, Unrelated Donors for Myeloid Malignancies [NCT00392782]	Phase 2	24 participants (Actual)	Interventional	2005-07-31	Terminated
Stem Cell Enriched, T Cell Depleted Haplocompatible Peripheral Blood Transplantation for Children With Myelodysplastic Disease, Leukemia, Marrow Failure Syndromes, or Severe Immunodeficiency Diseases [NCT00295971]	Phase 1	21 participants (Actual)	Interventional	2005-04-30	Completed
Continuous Infusion Thiotepa in High Grade Astrocytic Tumors of Childhood and Adolescence A UKCCSG Phase II Study Involving the Brain Tumour and New Agent Groups [NCT00313521]	Phase 2	30 participants (Anticipated)	Interventional	1995-06-30	Active, not recruiting
Multicenter Therapy Optimizing Study for Treatment of Children and Adolescents With Intracranial Medulloblastoma / PNET and Ependymoma [NCT00303810]		567 participants (Actual)	Interventional	2001-01-31	Completed
High Dose Paclitaxel Added to Cyclophosphamide and Thiotepa Followed by Autologous Stem Cell Rescue: A Phase I Trial in Advanced Breast Cancer [NCT00004174]	Phase 1	30 participants (Actual)	Interventional	1999-10-31	Completed
High-Dose Thiotepa With Autologous Stem Cell Rescue in Patients With Malignancies Refractory to Conventional Chemotherapy [NCT00003173]	Phase 2	36 participants (Anticipated)	Interventional	1997-09-30	Completed
High-Dose Consolidation With Escalating Doses of Melphalan and Thiotepa for Stage IV Breast Cancer [NCT00003899]	Phase 1	0 participants	Interventional	1999-01-31	Completed
Multi-Center, Open-Label Randomized Study of Single or Double Myeloablative Cord Blood Transplantation With or Without Infusion of Off-The-Shelf Ex Vivo Expanded Cryopreserved Cord Blood Progenitor Cells in Patients With Hematologic Malignancies [NCT01690520]	Phase 2	163 participants (Actual)	Interventional	2012-12-11	Completed
A Phase II Study of Myeloablative and Reduced-Intensity Conditioning Regimens for Children and Young Adults With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Stem Cell Transplantation [NCT02626715]	Phase 2	22 participants (Actual)	Interventional	2015-09-04	Completed
Allogeneic Transplantation After a Conditioning With Thiotepa, Busulfan and Fludarabin for the Treatment of Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas: a Phase II Multi-Center Trial [NCT01786018]	Phase 2	42 participants (Anticipated)	Interventional	2013-02-28	Recruiting
A Phase II Study Evaluating Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors for Prevention of GVHD [NCT02220985]	Phase 2	84 participants (Actual)	Interventional	2015-02-03	Active, not recruiting
A Phase II Multicentre, Randomized, Controlled Open-label Study on the Use of Anti-thymocyte Globulin and Rituximab for Immunomodulation of Graft-versus-host Disease in Allogeneic Matched Transplants for Non Malignancies [NCT01810926]	Phase 2	130 participants (Anticipated)	Interventional	2011-09-30	Recruiting
Prospective, Phase II Randomized Study to Compare Busulfan-fludarabine Reduced-intensity Conditioning (RIC) With Thiotepa-fludarabine RIC Regimen Prior to Allogeneic Transplantation of Hematopoietic Cells for the Treatment of Myelofibrosis [NCT01814475]	Phase 2	62 participants (Actual)	Interventional	2011-07-31	Completed
Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor [NCT01598025]		3 participants (Actual)	Interventional	2012-05-02	Terminated(stopped due to Closed due to poor accrual)
Haploidentical Donor Hematopoietic Progenitor Cell and Natural Killer Cell Transplantation With a TLI Based Conditioning Regimen in Patients With Hematologic Malignancies [NCT01807611]	Phase 2	82 participants (Actual)	Interventional	2013-05-16	Completed
A TRIAL OF INTENSIVE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL RECONSTITUTION FOR PATIENTS BETWEEN SIX AND SIXTY YEARS OF AGE, WITH NON-PROGRESSIVE GLIOBLASTOMA MULTIFORME OR DIFFUSE INTRINSIC BRAINSTEM TUMORS, FOLLOWING INITIAL LOCAL-FIELD IRRADIATION [NCT00002619]	Phase 2	60 participants (Anticipated)	Interventional	1994-09-30	Completed
PEDS024, Phase I/II Feasibility Study of Busulfan Fludarabine and Thiotepa Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation (HSCT) for Children With Non-Malignant Disorders [NCT03513328]	Phase 1/Phase 2	6 participants (Actual)	Interventional	2018-06-15	Completed
Delayed Infusion of Ex Vivo Anergized Peripheral Blood Mononuclear Cells Following CD34 Selected Peripheral Blood Stem Cell Transplantation From a Haploidentical Donor for Patients With Acute Leukemia and Myelodysplasia [NCT00376480]	Phase 1	19 participants (Actual)	Interventional	2005-06-30	Completed
Treatment of Stage IV Breast Cancer With Activated T Cells After Peripheral Blood Stem Cell Transplant (Pilot Phase II) [NCT00020722]	Phase 2	7 participants (Actual)	Interventional	2007-08-31	Terminated(stopped due to Lack of funding to continue study.)
Phase II Trial of Sequential High-Dose Alkylating Agents in Metastatic Breast Cancer [NCT00002680]	Phase 2	40 participants (Actual)	Interventional	1994-02-28	Completed
TREATMENT OF ISOLATED CNS RELAPSE OF ACUTE LYMPHOBLASTIC LEUKEMIA -- A PEDIATRIC ONCOLOGY GROUP-WIDE PHASE II STUDY [NCT00002704]	Phase 2	156 participants (Actual)	Interventional	1996-01-31	Completed
Phase I-II Study of Tandem Cycles of High Dose Chemotherapy Followed by Autologous Hematopoietic Stem Cell Support in Women With Persistent, Refractory or Recurrent Advanced (Stage III or IV), Epithelial Ovarian Cancer [NCT00003064]	Phase 1/Phase 2	30 participants (Anticipated)	Interventional	1997-01-31	Active, not recruiting
A Phase II Pilot Study of Sequential High Dose Chemotherapy and CD 34+ Selected Stem Cell Support Without Conventional-Dose Induction Chemotherapy for Women With Metastatic Breast Cancer [NCT00004900]	Phase 2	0 participants	Interventional	1999-10-31	Completed
A Phase II Multi-Institution Study of Docetaxel and Doxorubicin as Induction Therapy Followed by Sequential High Dose Chemotherapy and CD 34+ Selected Stem Cell Support for Women With Metastatic Breast Cancer [NCT00004906]	Phase 2	0 participants	Interventional	1999-10-31	Completed
A Phase I Study of Photochemically Treated Donor T-Cell Supplements in HLA Haplotype Mismatched Hematopoietic Stem Cell Transplantation [NCT00005092]	Phase 1	7 participants (Actual)	Interventional	1999-05-28	Completed
An International Randomised Clinical Trial of Therapeutic Interventions to Assess the Effects on Outcome in Adults With Acute Myeloid Leukaemia and High Risk Myelodysplasia Undergoing Allogeneic Stem Cell Transplantation. [NCT04217278]	Phase 2/Phase 3	333 participants (Actual)	Interventional	2020-01-27	Active, not recruiting
High-dose 131I-MIBG Treatment Incorporated Into Tandem High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With High-risk Neuroblastoma [NCT03061656]	Phase 2	40 participants (Anticipated)	Interventional	2009-01-01	Active, not recruiting
A Phase II Trial of CD34+ Enriched Transplants From HLA-Compatible Related or Unrelated Donors for Treatment of Patients With Leukemia or Lymphoma [NCT05565105]	Phase 2	100 participants (Anticipated)	Interventional	2024-03-31	Not yet recruiting
Megadose CD34 Selected Progenitor Cells for Transplantation in Patients With Advanced Hematological Malignant Diseases [NCT00038857]	Phase 2	29 participants (Actual)	Interventional	2001-09-30	Completed
Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation [NCT02790515]	Phase 2	52 participants (Anticipated)	Interventional	2016-07-14	Recruiting
A Pilot/Phase 1 Study of Immunosuppression-free Regulatory T-cell Graft-engineered Haploidentical Hematopoietic Cell Transplantation in Relapsed/Refractory and Ultra-High-risk AML/MDS [NCT04678401]	Phase 1	20 participants (Anticipated)	Interventional	2021-01-12	Recruiting
A Phase II Study of Thiotepa Added to Fludarabine and Melphalan as the Preparative Regime for Alternative Donor Transplantation [NCT03342196]	Phase 2	40 participants (Actual)	Interventional	2018-03-21	Active, not recruiting
Treatment Protocol for Relapsed Anaplastic Large Cell Lymphoma of Childhood and Adolescence [NCT00317408]		96 participants (Anticipated)	Interventional	2004-04-30	Active, not recruiting
Infusion of Off-the-Shelf Ex Vivo Expanded Cryopreserved Progenitor Cells to Facilitate the Engraftment of a Single CCR5Δ32 Homozygous or Heterozygous Cord Blood Unit in Patients With HIV and Hematological Malignancies [NCT04083170]	Phase 2	10 participants (Anticipated)	Interventional	2022-10-06	Recruiting
INFUSION OF ACTIVATED T CELLS AND LOW DOSE INTERLEUKIN 2 COMBINED WITH PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FOR THE TREATMENT OF WOMEN WITH METASTATIC BREAST CANCER: PHASE I/II [NCT00002780]	Phase 1/Phase 2	60 participants (Anticipated)	Interventional	1996-05-31	Active, not recruiting
Double Umbilical Cord Blood Transplantation for Patients With Malignant and Non-Malignant Disorders [NCT00801931]	Phase 1/Phase 2	1 participants (Actual)	Interventional	2007-09-06	Terminated(stopped due to Poor accrual)
A Phase I Trial of Sequential High Dose Chemotherapy Regimens Followed by Autologous or Syngeneic Peripheral Blood Stem Cell (PBSC) Rescue in Patients With Persistent Stage III/IV Ovarian Cancer [NCT00003080]	Phase 1	0 participants	Interventional	1996-09-30	Completed
Phase I/II Study of Samarium 153 as Part of a Double (Sequential) Autologous Bone Marrow Transplant (ABMT) for Patients With Stage IV Breast Cancer [NCT00003086]	Phase 1/Phase 2	12 participants (Anticipated)	Interventional	1997-03-31	Terminated(stopped due to no participants enrolled in a three year period)
Myeloablative Chemotherapy With Bone Marrow Rescue For Rare Poor-Prognosis Cancers [NCT00002515]	Phase 2	0 participants	Interventional	1992-10-31	Completed
A Phase II Trial of Thiotepa, Busulfan, and Melphalan Followed by Autologous or Syngeneic Marrow or Peripheral Blood Stem Cell Transplantation in Patients With Multiple Myeloma [NCT00003146]	Phase 2	0 participants	Interventional	1997-11-30	Completed
Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor [NCT00003398]	Phase 4	45 participants (Anticipated)	Interventional	1998-09-30	Completed
A RANDOMIZED, MULTI-CENTRE PHASE III TRIAL TO EVALUATE THE ROLE OF INTENSIFIED THERAPY WITH AUTOLOGOUS TRANSPLANTATION OF HEMATOPOIETIC STEM CELLS IN ADVANCED OR METASTATIC BREAST CANCER RESPONDING TO INDUCTION CHEMOTHERAPY [NCT00002870]	Phase 3	180 participants (Anticipated)	Interventional	1994-12-31	Completed
A Phase I Study of Thiotepa in Combination With Carboplatin and Topotecan With Peripheral Blood Progenitor Cell Support for the Treatment of Children With Recurrent or Refractory Solid Tumors. [NCT00003194]	Phase 1	24 participants (Anticipated)	Interventional	1997-07-31	Terminated(stopped due to Study enrollment did not meet expected goals)
PROSPECTIVE RANDOMISED EVALUATION OF HIGH-INTENSITY CHEMOTHERAPY WITH PERIPHERAL BLOOD PROGENITOR SUPPORT IN PATIENTS WITH HIGH RISK BREAST CANCER [NCT00002755]	Phase 3	600 participants (Anticipated)	Interventional	1995-11-30	Completed
A Randomised Comparative Trial of Highly Intensive Chemotherapy With Stem Cell Support vs. Relatively Intensive Chemotherapy (CMF 8 Cycles) in Breast Cancer Patients Node Positive Surgery, Having Received Primary Medical Therapy With an Anthracycline Regi [NCT00003680]	Phase 3	300 participants (Anticipated)	Interventional	1998-11-30	Active, not recruiting
A Phase I Study of the Chemoprotectant Amifostine With Autologous Stem Cell Transplantation for High Risk or Relapsed Pediatric Solid Tumors and Brain Tumors [NCT00003926]	Phase 1	13 participants (Actual)	Interventional	1998-11-30	Terminated(stopped due to Withdrawn due to slow accrual)
A Phase II Study of Cyclophosphamide, Thiotepa, and Carboplatin (CTC) as a Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Patients With Breast Cancer [NCT00005798]	Phase 2	209 participants (Actual)	Interventional	1995-07-31	Completed
A Phase I Trial of Melphalan and Thiotepa Followed by Autologous or Syngeneic Peripheral Blood Stem Cell (PBSC) Rescue in Patients With a Complete Response Following Standard Therapy for Stage III/IV Epithelial Ovarian Cancer [NCT00002977]	Phase 1	45 participants (Anticipated)	Interventional	1997-01-31	Completed
A Phase I/II Study in Metastatic Breast Cancer Patients Infused With Stromagen and Isolated, Mobilized, Autologous Peripheral Blood CD34+ Progenitor Cells After High-Dose Chemotherapy [NCT00003877]	Phase 1/Phase 2	30 participants (Anticipated)	Interventional	1998-09-30	Completed
NYU 05-40 PBMTC ONC-032P:High Dose Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue (ASCR) Followed by Continuation Therapy With 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors [NCT00528437]	Phase 2	46 participants (Actual)	Interventional	2005-10-31	Completed
Phase II Trial of Intensive, Short-Course Combination Chemotherapy in the Treatment of Newly Diagnosed Patients With Poor-Risk Nonlymphoblastic Lymphoma and Acute B-Lymphoblastic Leukemia and in Patients With Recurrent Non-Hodgkin's Lymphoma [NCT00002471]	Phase 2	0 participants	Interventional	1990-02-28	Completed
A Phase I Trial of Busulfan, Thiotepa and Melphalan Followed by Autologous or Syngeneic Peripheral Blood Stem Cell Transplantation and Followed by Total Marrow (Skeletal) Irradiation (TMI) in Patients With High-Risk Ewing's Sarcoma, PNET or Rhabdomyosarco [NCT00003081]	Phase 1	16 participants (Anticipated)	Interventional	1998-03-31	Completed
A Pilot Study of Intensive Chemotherapy With Peripheral Stem Cell Support for Infants With Malignant Brain Tumors [NCT00003141]	Phase 1	94 participants (Actual)	Interventional	1998-03-31	Completed
CD45A-Depleted Haploidentical Hematopoietic Progenitor Cell and Natural Killer Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation [NCT02259348]	Phase 2	12 participants (Actual)	Interventional	2014-10-31	Terminated(stopped due to Investigator's decision.)
Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotep [NCT00003273]	Phase 2	0 participants (Actual)	Interventional	1997-11-30	Withdrawn
Phase I/II Study of High Dose Topotecan, Mitoxantrone and Thiotepa (TMT) Followed by Autologous Stem Cell Transplant in Patients With Recurrent Platinum Resistant Ovarian Cancer [NCT00003297]	Phase 1/Phase 2	50 participants (Anticipated)	Interventional	1997-12-31	Completed
A Phase II Trial of Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma [NCT00588523]	Phase 2	60 participants (Actual)	Interventional	2002-09-30	Completed
Multicenter Phase II Study of Haploidentical Hematopoietic Cell Transplantation With CD3/CD19 Depleted Grafts After a Reduced Intensity Conditioning Regimen for Adult Patients With Acute Leukemia [NCT00961142]	Phase 2	23 participants (Actual)	Interventional	2009-06-30	Terminated(stopped due to slow recruitment)
Alkylator-Intense Conditioning Followed by Autologous Transplantation for Patients With High Risk or Relapsed Solid or CNS Tumors [NCT01505569]		20 participants (Anticipated)	Interventional	2011-10-20	Recruiting
Reduced Toxicity Conditioning Prior to Unrelated Cord Cell Transplantation for High Risk Myeloid Malignancies [NCT02333838]	Phase 2	31 participants (Actual)	Interventional	2015-05-31	Active, not recruiting
Autologous Blood and Marrow Transplantation for Hematologic Malignancies and Selected Solid Tumors [NCT00536601]		174 participants (Actual)	Interventional	2006-06-29	Completed
A Prospective Phase II Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy Followed by Allogeneic Stem Cell Transplantation as Treatment of Primary Progressive and Relapsed Aggressive Non-Hodgkin Lymphoma [NCT04121507]	Phase 2	60 participants (Actual)	Interventional	2019-06-24	Completed
A Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric and Adolescent-Young Adults Patients With High Risk Solid Tumors [NCT04530487]	Phase 2	40 participants (Anticipated)	Interventional	2020-08-19	Recruiting
A Phase II Study of Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD in Children [NCT01858740]	Phase 2	20 participants (Actual)	Interventional	2013-12-17	Completed
Clinical Study on the Efficacy and Safety of Auto-HSCT in Adult Patients With Burkitt Lymphoma, Lymphoblastic Lymphoma, and Acute Lymphoblastic Leukemia Who Received TCCA Conditioning Regimen [NCT06060782]	Phase 1	28 participants (Anticipated)	Interventional	2023-10-01	Recruiting
Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia [NCT00003816]	Phase 2/Phase 3	361 participants (Actual)	Interventional	1998-10-19	Completed
Randomized Phase II Study of Adriamycin/Cytoxan/Taxol (ACT) vs. Cytoxan, Thiotepa, Carboplatin (STAMP V) in Patients With High-Risk Primary Breast Cancer [NCT00004092]	Phase 2	72 participants (Actual)	Interventional	1999-05-31	Completed
Haploidentical Donor Hematopoietic Stem Cell Transplantation [NCT02660281]	Phase 1	74 participants (Actual)	Interventional	2015-10-31	Completed
Phase II Study of Palifermin With Leuprolide Acetate or Degarelix For the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation [NCT01746849]	Phase 2	82 participants (Actual)	Interventional	2012-12-31	Active, not recruiting
A Phase II Trial of Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma [NCT00003101]	Phase 2	60 participants (Anticipated)	Interventional	1997-08-31	Completed
Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID) [NCT03597594]	Phase 1/Phase 2	4 participants (Actual)	Interventional	2021-09-02	Active, not recruiting
A Pilot Study of Reduced Intensity Conditioning in Pediatric Patients <21 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood Transplantation [NCT00744692]	Phase 1	22 participants (Actual)	Interventional	2008-10-31	Completed
Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen [NCT02199041]	Phase 2	24 participants (Actual)	Interventional	2014-07-11	Terminated(stopped due to The study was halted early due to slow accrual.)
Pilot Study: Infusion of Off-the-Shelf Ex Vivo Expanded Cryopreserved Progenitor Cells (Dilanubicel) in the Setting of Single Cord Blood Transplantation for Patients With Hematologic Malignancies [NCT03399773]	Phase 2	15 participants (Anticipated)	Interventional	2022-05-10	Recruiting
Autologous Stem Cell Transplantation With CD34-Selected Peripheral Blood Stem Cells (PBSC) in Pediatric and Adult Patients With Severe Crohn's Disease [NCT00692939]	Phase 1/Phase 2	20 participants (Anticipated)	Interventional	2012-06-26	Recruiting
Phase II Trial of Fludarabine Combined With Intravenous Thiotepa and Allogeneic Hematopoietic Stem-cell Transplantation in Patients With Lymphatic Malignancies Including Multiple Myeloma, Non Hodgkin's, Hodgkin Lymphoma and CLL [NCT02507479]	Phase 2	24 participants (Anticipated)	Interventional	2015-09-30	Recruiting
A Pilot Study of Allogeneic Hematopoietic Cell Transplantation for Patients With High Grade Central Nervous System Malignancies [NCT04521946]	Phase 1	0 participants (Actual)	Interventional	2021-01-14	Withdrawn(stopped due to No participants enrolled.)
Phase II Study of Tandem Cycle Dose-Intense Chemotherapy of Melphalan and Carboplatin, Thiotepa and Cyclophosphamide (STMP V) ± Trastuzumab Followed by Helical Tomotherapy or Local Regional Radiation Therapy for Stage IV Metastatic and Stage IIIB/C Breast [NCT00182793]	Phase 2	32 participants (Actual)	Interventional	2005-07-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00003199 (3) [back to overview]	Event-free Survival
NCT00003199 (3) [back to overview]	Overall Survival
NCT00003199 (3) [back to overview]	Number of Participants With Toxicity of a Combination of Low-dose IL-2 and GM-CSF
NCT00003816 (4) [back to overview]	4 yr OS
NCT00003816 (4) [back to overview]	CR Rate
NCT00003816 (4) [back to overview]	Toxicity/TRM at Day 100
NCT00003816 (4) [back to overview]	4 Year PFS
NCT00004092 (2) [back to overview]	Five-Year Overall Survival
NCT00004092 (2) [back to overview]	Five-Year Relapse-free Survival
NCT00038857 (1) [back to overview]	Number of Participants With Absolute Neutrophil Count Engraftment
NCT00047320 (6) [back to overview]	Number of Patients Experiencing Toxic Death
NCT00047320 (6) [back to overview]	Occurrence of Non-hematological Grade 4 Toxicity Occurrence of Nonhematological Grade 4 Toxicity
NCT00047320 (6) [back to overview]	Overall Survival (OS)
NCT00047320 (6) [back to overview]	Progression-free Survival (PFS)
NCT00047320 (6) [back to overview]	The Probability of Event-free Survival (EFS)
NCT00047320 (6) [back to overview]	Response to Induction Chemotherapy
NCT00067002 (5) [back to overview]	Number of Participants Severity of Acute GVHD by Treatment Arm
NCT00067002 (5) [back to overview]	Number of Participants With Engraftment
NCT00067002 (5) [back to overview]	Rate of Acute Graft Versus Host Disease (GVHD)
NCT00067002 (5) [back to overview]	Time To Neutrophil Engraftment
NCT00067002 (5) [back to overview]	Rate of Chronic GVHD
NCT00145626 (13) [back to overview]	Frequency of and Clinical Relevance of Minimal Residual Disease (MRD) Before and After Transplantation
NCT00145626 (13) [back to overview]	Kinetics of Lymphohematopoietic Reconstitution
NCT00145626 (13) [back to overview]	Factors Affecting One-year Survival: Minimal Residual Disease (MRD)
NCT00145626 (13) [back to overview]	Factors Affecting One-year Survival: Match N/6 HLA Loci
NCT00145626 (13) [back to overview]	Factors Affecting One-year Survival: Donor Type
NCT00145626 (13) [back to overview]	Factors Affecting One-year Survival: Disease Status at HSCT
NCT00145626 (13) [back to overview]	One-year Survival
NCT00145626 (13) [back to overview]	Number of Transplant-Related Adverse Outcomes: Regimen-Related Mortality
NCT00145626 (13) [back to overview]	Number of Transplant-Related Adverse Outcomes: Fatal Acute Graft-Versus Host Disease (GVHD)
NCT00145626 (13) [back to overview]	Number of Transplant-Related Adverse Outcomes: Engraftment Failure
NCT00145626 (13) [back to overview]	Factors Affecting One-year Survival: Median Dose of NK Cells
NCT00145626 (13) [back to overview]	Factors Affecting One-year Survival: Median Dose of CD34
NCT00145626 (13) [back to overview]	Factors Affecting One-year Survival: Median Age of Donor at HSCT
NCT00182793 (2) [back to overview]	5-Year Relapse-free Survival Rate
NCT00182793 (2) [back to overview]	5-Year Overall Survival Rate
NCT00238433 (2) [back to overview]	Disease-Free Survival
NCT00238433 (2) [back to overview]	Therapy-Related Toxicities
NCT00336024 (10) [back to overview]	Number of Participants With Chronic Central Hypothyroidism
NCT00336024 (10) [back to overview]	Rates of Nutritional Toxicities
NCT00336024 (10) [back to overview]	Rates of Gastrointestinal Toxicities
NCT00336024 (10) [back to overview]	Median/Range of Patients for Total Quality of Life (QOL) Score, Intelligence Quotient (IQ) and Processing Speed Index (PSI).
NCT00336024 (10) [back to overview]	Percentage of Participants With Event Free Survival (EFS)
NCT00336024 (10) [back to overview]	Percentage of Participants With Any Acute Adverse Events
NCT00336024 (10) [back to overview]	Number of Participants With Secondary Malignancies
NCT00336024 (10) [back to overview]	Number of Participants With Chronic Primary Hypothyroidism/Subclinical Compensatory HypothyroidismHypothyroidism/Subclinical Compensatory Hypothyroidism
NCT00336024 (10) [back to overview]	Number of Participants With Chronic Diabetes Insipidus
NCT00336024 (10) [back to overview]	Number of Participants With Chronic Low Somatomedin C
NCT00357396 (1) [back to overview]	Overall Objective Response
NCT00382109 (6) [back to overview]	Relative Contribution of ALL Blasts to the Donor Immune Response as a Cause of Relapse Post Transplantation (Correlating Development of aGVHD With Relapse)
NCT00382109 (6) [back to overview]	Rate of Relapses
NCT00382109 (6) [back to overview]	Estimated Transplant Related Mortality Percentage
NCT00382109 (6) [back to overview]	Estimated Rate of Overall Chronic Graft VS Host Disease
NCT00382109 (6) [back to overview]	Estimated Rate of Acute Graft VS Host Disease (GVHD)
NCT00382109 (6) [back to overview]	Estimated Percentage of Participants With Event Free Survival
NCT00392782 (7) [back to overview]	Transplant-related Mortality
NCT00392782 (7) [back to overview]	Overall Survival
NCT00392782 (7) [back to overview]	Incidence of Graft Failure
NCT00392782 (7) [back to overview]	Incidence of Grade II-IV Acute Graft-vs-host Disease (GVHD)
NCT00392782 (7) [back to overview]	Incidence of Disease-free Survival
NCT00392782 (7) [back to overview]	Incidence of Disease Relapse
NCT00392782 (7) [back to overview]	Incidence of Chronic Graft-versus-host Disease (GVHD)
NCT00423514 (1) [back to overview]	Participants Evaluated for Early Post-transplant Regimen-related Severe Morbidity (Grade III to IV Nonhematologic Toxicity) and Mortality as Measured by the NCI Cancer Therapy Evaluation Program CTCAE v 3.0
NCT00429182 (2) [back to overview]	Number of Participants With Reduction in CTCs Following High-dose Chemotherapy With Purged Autologous Stem Cell Products
NCT00429182 (2) [back to overview]	Median Progression Free Survival (PFS)
NCT00432094 (5) [back to overview]	Numbers of Patients Unable to Mobilize Peripheral Blood Stem Cells
NCT00432094 (5) [back to overview]	Overall Survival (OS)
NCT00432094 (5) [back to overview]	Engraftment of Platelets
NCT00432094 (5) [back to overview]	Disease-free Survival (DFS)
NCT00432094 (5) [back to overview]	Engraftment of Neutrophils
NCT00450983 (4) [back to overview]	Risk of Developing Grades III-IV Acute Graft-vs-host Disease (GVHD)
NCT00450983 (4) [back to overview]	Risk for Mortality From Infection Before Day 180
NCT00450983 (4) [back to overview]	Risk for Life-threatening Infections
NCT00450983 (4) [back to overview]	Risk for Graft Failure
NCT00536601 (8) [back to overview]	Progression-free Survival (PFS) Distribution of Patients With HL, NHL, and MM for Each Disease-specific High-dose Therapy Regimen, Estimate Provided for 10-yr PFS (Median Follow-up Time in Survivors)
NCT00536601 (8) [back to overview]	Progression-free Survival (PFS) Distribution of Patients With HL, NHL, and MM for Each Disease-specific High-dose Therapy Regimen, Estimate Provided for 10-yr PFS (Median Follow-up Time in Survivors)
NCT00536601 (8) [back to overview]	Progression-free Survival (PFS) Distribution of Patients With HL, NHL, and MM for Each Disease-specific High-dose Therapy Regimen, Estimate Provided for 10-yr PFS (Median Follow-up Time in Survivors)
NCT00536601 (8) [back to overview]	Progression-free Survival (PFS) Distribution of Patients With HL, NHL, and MM for Each Disease-specific High-dose Therapy Regimen, Estimate Provided for 10-yr PFS (Median Follow-up Time in Survivors)
NCT00536601 (8) [back to overview]	Overall Survival, Presented as the Estimate at 10-yrs (Median Follow-up Time in Survivors)
NCT00536601 (8) [back to overview]	Regimen-related Toxicity Grade 2-4 in Any Organ (Measured by Bearman Score, Values Range From 0 (None) to 4 (Fatal))
NCT00536601 (8) [back to overview]	Response Rate (Complete Remission)
NCT00536601 (8) [back to overview]	Progression-free Survival (PFS) Distribution of Patients With HL, NHL, and MM for Each Disease-specific High-dose Therapy Regimen, Estimate Provided for 10-yr PFS (Median Follow-up Time in Survivors)
NCT00554788 (3) [back to overview]	Response Rate to the Induction Phase of the Regimen
NCT00554788 (3) [back to overview]	Event-free Survival (EFS)
NCT00554788 (3) [back to overview]	Percentage of Participants With Adverse Events as Assessed by the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0
NCT00566696 (7) [back to overview]	Event-free Survival (EFS)
NCT00566696 (7) [back to overview]	Incidence of Regimen-related Mortality
NCT00566696 (7) [back to overview]	Overall Survival (OS)
NCT00566696 (7) [back to overview]	Incidence of Non-hematologic Regimen-related Toxicities
NCT00566696 (7) [back to overview]	To Estimate the Cumulative Incidence of Relapse for Research Participants Who Receive This Study Treatment.
NCT00566696 (7) [back to overview]	To Estimate the Rate of Overall Grade III-IV Acute GVHD, and the Rate and Severity of Chronic GVHD in Research Participants.
NCT00566696 (7) [back to overview]	Disease-Free Survival (DFS)
NCT00567567 (14) [back to overview]	Duration of Greater Than or Equal to Grade 3 Neutropenia
NCT00567567 (14) [back to overview]	Intraspinal Extension
NCT00567567 (14) [back to overview]	OS in Patients 12-18 Months, Stage 4, MYCN Nonamplified Tumor/Unfavorable Histopathology/Diploid DNA Content/Indeterminant Histology/Ploidy and Patients > 547 Days, Stage 3, MYCN Nonamplified Tumor AND Unfavorable Histopathology/Indeterminant Histology
NCT00567567 (14) [back to overview]	Duration of Greater Than or Equal to Grade 3 Thrombocytopenia
NCT00567567 (14) [back to overview]	EFS Pts Non-randomly Assigned to Single CEM (12-18 Mths, Stg. 4, MYCN Nonamplified Tumor/Unfavorable or Indeterminant Histopathology/Diploid DNA Content & Pts>547 Days, Stg.3, MYCN Nonamplified Tumor AND Unfavorable or Indeterminant Histopathology).
NCT00567567 (14) [back to overview]	Event-free Survival Rate
NCT00567567 (14) [back to overview]	Incidence Rate of Local Recurrence
NCT00567567 (14) [back to overview]	Enumeration of Peripheral Blood Cluster of Differentiation (CD)3, CD4, and CD8 Cells
NCT00567567 (14) [back to overview]	Type of Surgical or Radiotherapy Complication
NCT00567567 (14) [back to overview]	Topotecan Systemic Clearance
NCT00567567 (14) [back to overview]	Surgical Response
NCT00567567 (14) [back to overview]	Response After Induction Therapy
NCT00567567 (14) [back to overview]	Proportion of Patients With a Polymorphism
NCT00567567 (14) [back to overview]	Peak Serum Concentration of Isotretinoin in Patients Enrolled on Either A3973, ANBL0032, ANBL0931, ANBL0532 and Future High Risk Studies
NCT00588523 (2) [back to overview]	Progession Free Survival
NCT00588523 (2) [back to overview]	Number of Participants Evaluated for Toxicities
NCT00593554 (7) [back to overview]	Frequency of Infection
NCT00593554 (7) [back to overview]	Regimen-related Toxicity
NCT00593554 (7) [back to overview]	Time to Neutrophil Engraftment
NCT00593554 (7) [back to overview]	Time to Platelet Engraftment
NCT00593554 (7) [back to overview]	Treatment-related Mortality (TRM) Rate at 6 Months After Transplantation
NCT00593554 (7) [back to overview]	Acute Graft vs. Host Disease (GvHD)
NCT00593554 (7) [back to overview]	Chronic Graft vs. Host Disease (GvHD)
NCT00653068 (4) [back to overview]	Event-free Survival
NCT00653068 (4) [back to overview]	Overall Survival (OS)
NCT00653068 (4) [back to overview]	Toxic Death
NCT00653068 (4) [back to overview]	Non-hematological Toxicity Associated With Chemotherapy: Grade 3 or Higher During Protocol Therapy
NCT00739141 (4) [back to overview]	Percentage of Participants With Sustained CB-derived Platelet Engraftment
NCT00739141 (4) [back to overview]	Percentage of Participants With Sustained CB-derived Neutrophil Engraftment
NCT00739141 (4) [back to overview]	Number of Participants With Neutrophil Recovery Post Allograft for Haplo-dCBT Recipients
NCT00739141 (4) [back to overview]	Progression Free Survival/PFS at 1 Year Post UCBT.
NCT00744692 (9) [back to overview]	To Describe the Incidence of Grade 3-4 Organ Toxicity
NCT00744692 (9) [back to overview]	Determine the Feasibility of Attaining Acceptable Rates of Donor Cell Engraftment (>25% Donor Cells at 180 Days) Following RIC Regimens in Children < 21 Years Receiving UCBT for Non-malignant Disorders.
NCT00744692 (9) [back to overview]	To Describe Incidence of Acute Graft Versus Host Disease (GVHD) (II - IV)
NCT00744692 (9) [back to overview]	To Describe the Pace of Neutrophil Recovery
NCT00744692 (9) [back to overview]	To Describe the Pace of Platelet Recovery
NCT00744692 (9) [back to overview]	To Determine the Overall Survival at day180 Post-transplant
NCT00744692 (9) [back to overview]	To Evaluate Long-term Complications, Such as Sterility, Endocrinopathy, and Growth Failure
NCT00744692 (9) [back to overview]	To Evaluate the Incidence of Late Graft Failures at 2 Years Post-transplant
NCT00744692 (9) [back to overview]	To Evaluate the Pace of Immune Reconstitution.
NCT00857389 (7) [back to overview]	Engraftment
NCT00857389 (7) [back to overview]	Graft vs Host Disease (GVHD)
NCT00857389 (7) [back to overview]	Number of Participants With Disease Free Survival
NCT00857389 (7) [back to overview]	Number of Participants With Serious Adverse Events
NCT00857389 (7) [back to overview]	Number of Participants With Survival Rate at 100 Days Post-transplant
NCT00857389 (7) [back to overview]	Overall Survival Rate
NCT00857389 (7) [back to overview]	Relapse Rate of Participants Treated With Thiotepa, Busulfan, and Clofarabine
NCT00914940 (4) [back to overview]	Number of Participants Who Did Not Engraft After Receiving a CD45RA+ T Cell Depleted PBSC Transplant
NCT00914940 (4) [back to overview]	Transplant-related Mortality by Day 100
NCT00914940 (4) [back to overview]	Number of Participants With Chronic GVHD
NCT00914940 (4) [back to overview]	Number of Participants Who Have Relapsed Within 5 Years of CD45RA+ T Cell Depleted PBSC Transplant
NCT00943800 (3) [back to overview]	Overall Survival- Percentage of Participants Who Survived at 2 Years and 5 Years
NCT00943800 (3) [back to overview]	Percentage of Participants With Neutrophil Engraftment
NCT00943800 (3) [back to overview]	Percentage of Participants With Incidence of Acute (Grade II-IV) and Chronic Graft-vs-host Disease(GVHD)
NCT01010217 (6) [back to overview]	cGVHD
NCT01010217 (6) [back to overview]	Disease Free Survival
NCT01010217 (6) [back to overview]	Engraftments
NCT01010217 (6) [back to overview]	Grade III-IV aGVHD
NCT01010217 (6) [back to overview]	Number of Participants With Non Related Mortality (NRM)
NCT01010217 (6) [back to overview]	Number of Participants With Non-relapse Mortality (NRM)
NCT01050764 (6) [back to overview]	Overall Survival (OS), 1 Year
NCT01050764 (6) [back to overview]	Maximum-tolerated Dose (MTD) of Regulatory and Conventional T-cells
NCT01050764 (6) [back to overview]	Median Overall Survival (OS)
NCT01050764 (6) [back to overview]	Serious Infections
NCT01050764 (6) [back to overview]	To Measure the Incidence and Severity of Acute and Chronic GvHD
NCT01050764 (6) [back to overview]	Acute Graft-versus-Host-Disease (aGvHD)
NCT01119066 (6) [back to overview]	Survival and Disease-free Survival (DFS)
NCT01119066 (6) [back to overview]	The Incidence of Durable Hematopoietic Engraftment for T-cell Depleted Transplants Fractionated by the CliniMACS System Administered After Each of the Four Disease Targeted Cytoreduction Regimens.
NCT01119066 (6) [back to overview]	Survival and Disease-free Survival (DFS)
NCT01119066 (6) [back to overview]	Survival and Disease-free Survival (DFS)
NCT01119066 (6) [back to overview]	Number of Participants With Acute and Chronic GVHD Following T-cell Depleted, CD34+ Progenitor Cell Enriched Transplants Fractionated by the CliniMACS System.
NCT01119066 (6) [back to overview]	Incidence of Non-relapse Mortality (Transplant-related Mortality) Following Each Cytoreduction Regimen and a Transplant Fractionated by the CliniMACS System.
NCT01690520 (6) [back to overview]	Time to Platelet Engraftment (20k)
NCT01690520 (6) [back to overview]	Proportion of Participants With Chronic Graft Versus Host Disease
NCT01690520 (6) [back to overview]	Overall Survival
NCT01690520 (6) [back to overview]	Non-relapse Mortality
NCT01690520 (6) [back to overview]	Proportion of Patients With Severe Acute Graft Versus Host Disease
NCT01690520 (6) [back to overview]	Time to Neutrophil Engraftment
NCT01807611 (6) [back to overview]	Event-free Survival
NCT01807611 (6) [back to overview]	Number of Transplant Recipients With Acute and/or Chronic Graft Versus Host Disease (GVHD)
NCT01807611 (6) [back to overview]	Number of Transplant Recipients With Malignant Relapse
NCT01807611 (6) [back to overview]	Number of Transplant Recipients With Successful Engraftment
NCT01807611 (6) [back to overview]	Number of Transplant Recipients With Transplant-related Mortality (TRM)
NCT01807611 (6) [back to overview]	Overall Survival
NCT02199041 (9) [back to overview]	Number of Participants With Overall Survival (OS)
NCT02199041 (9) [back to overview]	Number of Participants With Neutrophil Engraftment
NCT02199041 (9) [back to overview]	Number of Participants With Malignant Relapse
NCT02199041 (9) [back to overview]	Number of Participants With Transplant-related Morbidity
NCT02199041 (9) [back to overview]	Number of Participants by Severity With Chronic Graft Versus Host Disease (GVHD) in the First 100 Days After HCT
NCT02199041 (9) [back to overview]	Number of Participants With Event-free Survival (EFS)
NCT02199041 (9) [back to overview]	Number of Participants by Severity With Acute Graft Versus Host Disease (GVHD) in the First 100 Days After HCT
NCT02199041 (9) [back to overview]	Number of Participants With Transplant-related Mortality (TRM)
NCT02199041 (9) [back to overview]	Number of Participants With Secondary Graft Failure
NCT02259348 (9) [back to overview]	Mean of Days to Absolute Neutrophil Count (ANC) Engraftment
NCT02259348 (9) [back to overview]	Median Days to Absolute Neutrophil Count (ANC) Engraftment
NCT02259348 (9) [back to overview]	Overall Survival (OS)
NCT02259348 (9) [back to overview]	Percentage of Participants Engrafted by Day 42 Post-transplant
NCT02259348 (9) [back to overview]	Rate of Transplant-related Mortality (TRM)
NCT02259348 (9) [back to overview]	Incidence and Severity of Chronic GvHD
NCT02259348 (9) [back to overview]	Incidence of Malignant Relapse
NCT02259348 (9) [back to overview]	Event-free Survival (EFS)
NCT02259348 (9) [back to overview]	Incidence and Severity of Acute GvHD
NCT02757885 (12) [back to overview]	Event-free Survival (EFS) Rate
NCT02757885 (12) [back to overview]	Frequency of Stroke
NCT02757885 (12) [back to overview]	Infection Rate
NCT02757885 (12) [back to overview]	Late Graft Rejection Rate
NCT02757885 (12) [back to overview]	Cumulative Incidence of Neutrophil Engraftment and Platelet Engraftment.
NCT02757885 (12) [back to overview]	Veno-occlusive Disease (VOD) Rate
NCT02757885 (12) [back to overview]	Rate of Central Nervous System (CNS) Toxicity
NCT02757885 (12) [back to overview]	Rate of Disease Recurrence
NCT02757885 (12) [back to overview]	Primary Graft Rejection Rate
NCT02757885 (12) [back to overview]	Overall Survival Rate
NCT02757885 (12) [back to overview]	Chimerism Rate Following Hematopoietic Cell Transplantation for Sickle Cell Disease
NCT02757885 (12) [back to overview]	Frequency of Idiopathic Pneumonia Syndrome (IPS)
NCT03513328 (8) [back to overview]	Assessment of Minimum Effective Dose (MED) of Thiotepa
NCT03513328 (8) [back to overview]	Evaluation of Transplant-related Mortality
NCT03513328 (8) [back to overview]	Number of Participants With Grade 2-4 Acute Graft-versus-host Disease (GVDH)
NCT03513328 (8) [back to overview]	Percentage of Participants With Chronic Graft-versus-host Disease (cGVHD)
NCT03513328 (8) [back to overview]	Percentage of Subjects Alive at 24 Months Post Transplant (OS)
NCT03513328 (8) [back to overview]	Percentage of Subjects With Graft Rejection/Failure.
NCT03513328 (8) [back to overview]	Percentage of Subjects Without Disease Recurrence Who Are Alive at 24 Months Post Transplant
NCT03513328 (8) [back to overview]	Percentage of Participants With Transplant-related Complications
NCT03786783 (5) [back to overview]	Response Rate
NCT03786783 (5) [back to overview]	Percentage of Participants With Unacceptable Toxicity
NCT03786783 (5) [back to overview]	Overall Survival
NCT03786783 (5) [back to overview]	Event-free Survival
NCT03786783 (5) [back to overview]	"Percentage of Participants Who Are Feasibility Failure"

Event-free Survival

Event-free survival of patients treated for inflammatory (Stage IIIb) and responsive stage IV breast cancer with BUMELTT and PBSC support and low dose immunotherapy with IL2 and GM-CSF. (NCT00003199)
Timeframe: 11 years

Intervention	Participants (Count of Participants)
	Stage IIIB Disease	Stage IV Disease
TX/Maintenance Therapy for Stage IIIB/IV Breast Cancer	11	9

Intervention	Participants (Count of Participants)
	Responder	Non-Responder
Radiation Therapy (CR From Induction)	74	11

Intervention	Participants (Count of Participants)
	Grade ≤ 2	Grade ≥ 3	No GVHD
Expanded CB Arm	15	2	27
Un-Manipulated CB Arm	20	6	19

Intervention	Participants (Count of Participants)
	Overall Chronic GVHD	Limited	Extensive
Expanded CB Arm	20	14	13
Un-Manipulated CB Arm	16	10	9

Intervention	Participants (Count of Participants)
	Patient 172467502			Patient 172467503	Patient 172467501	Patient 272467501	Patient 272467502	Patient 272467503	Patient 372467501	Patient 372467502	Patient 372467503	Patient 472467501	Patient 472467502	Patient 472467503
	Data Not Collected	Positive MRD	Negative MRD
Study Participants: 1 Year Post HSCT	1
Study Participants: 5 Years Post HSCT	1
Study Participants: 1 Year Post HSCT	0
Study Participants: Before HSCT	0
Study Participants: Before HSCT	1
Study Participants: 5 Years Post HSCT	0

Intervention	cells *10^3/µl (Median)
	CD3 Lymphocyte	CD3 Gamma Delta	CD4 Lymphocyte	CD8 Lymphocyte	CD19 Lymphocyte	CD56 Lymphocyte	CD4/CD8 Ratio	Absolute Lymphocyte Value
0-3 Months After HSCT	0.22	0.00	0.13	0.01	0.26	0.36	2.60	0.88
1-2 Years After HSCT	1.65	0.70	0.96	0.61	0.45	0.22	1.88	2.59
2-3 Years After HSCT	2.88	0.24	1.56	1.05	0.56	0.32	1.38	3.76
3-4 Years After HSCT	2.65	0.21	1.33	1.10	0.56	0.34	1.30	3.65
3-6 Months After HSCT	0.57	0.04	0.42	0.09	0.48	0.33	5.53	1.29
4-5 Years After HSCT	1.87	0.38	1.94	0.70	0.43	0.19	1.30	2.40
6-9 Months After HSCT	1.15	0.08	0.92	0.29	0.61	0.20	3.36	1.95
9-12 Months After HSCT	2.24	0.09	1.37	0.36	0.52	0.19	1.90	2.90

Intervention	participants (Number)
	Negative for MRD	Positive for MRD
Alive	2	1
Expired	1	0
Study Participants	3	1

Intervention	participants (Number)
	3/6 HLA Loci	4/6 HLA Loci
Alive	6	1
Expired	3	4
Study Participants	9	5

Intervention	participants (Number)
	Active Disease	Complete Remission-1	Complete Remission-2	Progressive Disease	Relapse
Alive	0	6	0	1	0
Expired	1	2	1	0	3
Study Participants	1	8	1	1	3

Intervention	Participants (Count of Participants)
	3 months	6 months	9 months	12 months	18 months	24 months
Busulfan/Melphalan/Thiotepa	34	30	28	25	24	22

Intervention	Participants (Count of Participants)
	Dermatological Toxicities	Gastrointestinal Toxicities	Immune System Toxicites	Infections	Metabolic Toxicities	Respiratory Toxicities	Vascular Toxicities
Busulfan/Melphalan/Thiotepa	3	26	1	33	3	2	1

Intervention	percentage of participants (Number)
BuCy	56.4
CyTBI	56.5
FluMel	38.2
VpCyTBI	39.1
Other	53.3

Intervention	Participants (Count of Participants)
BuCy	42
CyTBI	55
FluMel	134
VpCyTBI	18
Other	7

Intervention	percentage of participants (Number)
BuCy	49.1
CyTBI	52.2
FluMel	33.2
VpCyTBI	26.1
Other	40

Intervention	Participants (Count of Participants)
Arm I (Patients Treated Without Methotrexate (MTX))	1
Arm II (Patients Treated With MTX)	1

Intervention	Participants (Count of Participants)
	Nutritional Disorders Induction Cycle I	No Nutritional Disorders Induction Cycle I	Nutritional Disorders Induction Cycle II	No Nutritional Disorders Induction Cycle II	Nutritional Disorders Induction Cycle III	No Nutritional Disorders Induction Cycle III	Nutritional Disorders Consolidation Cycle I	No Nutritional Disorders Consolidation Cycle I	Nutritional Disorders Consolidation Cycle II	No Nutritional Disorders Consolidation Cycle II	Nutritional Disorders Consolidation Cycle III	No Nutritional Disorders Consolidation Cycle III
Arm I (Patients Treated Without Methotrexate (MTX))	10	29	13	26	7	32	12	27	9	30	10	29
Arm II (Patients Treated With MTX)	17	21	13	25	12	26	8	30	5	33	5	33

Intervention	Participants (Count of Participants)
	GI Tox Induction Cycle I	No GI Tox Induction Cycle I	GI Tox Induction Cycle II	No GI Tox Induction Cycle II	GI Tox Induction Cycle III	No GI Tox Induction Cycle III	GI Tox Consolidation Cycle I	No GI Tox Consolidation Cycle I	GI Tox Consolidation Cycle II	No GI Tox Consolidation Phase II	GI Tox Consolidation Cycle III	No GI Tox Consolidation Cycle III
Arm I (Patients Treated Without Methotrexate (MTX))	8	31	4	35	4	35	11	28	7	32	5	34
Arm II (Patients Treated With MTX)	12	26	10	28	8	30	14	24	10	28	6	32

Intervention	scores on a scale (Median)
	Total Quality of Life Score	Intelligence Quotient	Processing Speed Index
Arm I (Patients Treated Without Methotrexate (MTX))	60.5	77.0	82.0
Arm II (Patients Treated With MTX)	56.5	78.5	89.0

Intervention	percentage of participants with EFS (Number)
Arm I (Patients Treated Without Methotrexate (MTX))	43.6
Arm II (Patients Treated With MTX)	54.9

Intervention	percentage of participants (Number)
Arm I (Patients Treated Without Methotrexate (MTX))	97.4
Arm II (Patients Treated With MTX)	97.2

Intervention	participants (Number)
	Very Good Partial Response (VGPR)	Complete Response (CR)
Patients With HIGH RISK EWING'S SARCOMA FAMILY TUMOR	4	1

Intervention	percentage of participants (Number)
	Experienced aGVHD, later relapsed	No aGVHD occurence, relapsed
All Patients	5	24

Intervention	Participants (Count of Participants)
Dose Level 1: Clofarabine at 20 mg/m^2/Dose x 5 + THIO-MEL	31
Dose Level 2: Clofarabine at 30 mg/m^2/Dose x 5 + THIO-MEL	7

Intervention	Proportion of participants (Number)
Acute Leukemia	33
Hodgkin Lymphoma	61
Non-Hodgkin Lymphoma	45
MM/Amyloid	39
Solid Tumors	46

thiotepa

Description

Cross-References

Synonyms (202)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Drug Classes (1)

Protein Targets (70)

Potency Measurements

Inhibition Measurements

Biological Processes (213)

Molecular Functions (83)

Ceullar Components (47)

Bioassays (177)

Research

Studies (2,574)

Market Indicators

Research Demand Index: 55.32

Study Types

Clinical Trials (219)

Trial Overview

Trial Outcomes

Event-free Survival

Overall Survival

Number of Participants With Toxicity of a Combination of Low-dose IL-2 and GM-CSF

4 yr OS

CR Rate

Toxicity/TRM at Day 100

4 Year PFS

Five-Year Overall Survival

Five-Year Relapse-free Survival

Number of Participants With Absolute Neutrophil Count Engraftment

Number of Patients Experiencing Toxic Death

Occurrence of Non-hematological Grade 4 Toxicity Occurrence of Nonhematological Grade 4 Toxicity

Overall Survival (OS)

Progression-free Survival (PFS)

The Probability of Event-free Survival (EFS)

Response to Induction Chemotherapy

Number of Participants Severity of Acute GVHD by Treatment Arm

Number of Participants With Engraftment

Rate of Acute Graft Versus Host Disease (GVHD)

Time To Neutrophil Engraftment

Rate of Chronic GVHD

Frequency of and Clinical Relevance of Minimal Residual Disease (MRD) Before and After Transplantation

Kinetics of Lymphohematopoietic Reconstitution

Factors Affecting One-year Survival: Minimal Residual Disease (MRD)

Factors Affecting One-year Survival: Match N/6 HLA Loci

Factors Affecting One-year Survival: Donor Type

Factors Affecting One-year Survival: Disease Status at HSCT

One-year Survival

Number of Transplant-Related Adverse Outcomes: Regimen-Related Mortality

Number of Transplant-Related Adverse Outcomes: Fatal Acute Graft-Versus Host Disease (GVHD)

Number of Transplant-Related Adverse Outcomes: Engraftment Failure

Factors Affecting One-year Survival: Median Dose of NK Cells

Factors Affecting One-year Survival: Median Dose of CD34

Factors Affecting One-year Survival: Median Age of Donor at HSCT

5-Year Relapse-free Survival Rate

5-Year Overall Survival Rate

Disease-Free Survival

Therapy-Related Toxicities

Number of Participants With Chronic Central Hypothyroidism

Rates of Nutritional Toxicities

Rates of Gastrointestinal Toxicities

Median/Range of Patients for Total Quality of Life (QOL) Score, Intelligence Quotient (IQ) and Processing Speed Index (PSI).

Percentage of Participants With Event Free Survival (EFS)

Percentage of Participants With Any Acute Adverse Events

Number of Participants With Secondary Malignancies

Number of Participants With Chronic Primary Hypothyroidism/Subclinical Compensatory HypothyroidismHypothyroidism/Subclinical Compensatory Hypothyroidism

Number of Participants With Chronic Diabetes Insipidus

Number of Participants With Chronic Low Somatomedin C

Overall Objective Response

Relative Contribution of ALL Blasts to the Donor Immune Response as a Cause of Relapse Post Transplantation (Correlating Development of aGVHD With Relapse)

Intervention	percentage of participants (Number)
	Abdominal pain	Acute kidney injury	Alanine aminotransferase increased	Anemia	Anorexia	Apnea	Aspartate aminotransferase increased	Catheter related infection	Dehydration	Depressed level of consciousness	Diarrhea	Encephalopathy	Enterocolitis	Enterocolitis infectious	Esophagitis	Febrile neutropenia	Fever	GGT increased	Gastric hemorrhage	Hearing impaired	Hypermagnesemia	Hypertension	Hypoalbuminemia	Hypocalcemia	Hypoglycemia	Hypokalemia	Hypomagnesemia	Hyponatremia	Hypophosphatemia	Hypotension	Hypoxia	Infections and infestations - Other, specify	Lower gastrointestinal hemorrhage	Lung infection	Lymphocyte count decreased	Mucositis oral	Nausea	Nervous system disorders - Other, specify	Neutrophil count decreased	Oral pain	Pain	Peripheral motor neuropathy	Pharyngeal mucositis	Platelet count decreased	Pneumonitis	Rectal pain	Seizure	Sepsis	Sinus tachycardia	Sinusitis	Skin infection	Upper respiratory infection	Vomiting	White blood cell decreased
Stage 2/3 Patients	0	0	0	0	11.1	0	0	11.1	0	0	5.6	0	0	5.6	0	55.6	11.1	0	0	11.1	5.6	0	0	5.6	0	27.8	5.6	11.1	22.2	0	0	27.8	0	16.7	0	5.6	16.7	0	5.6	0	0	5.6	0	5.6	5.6	0	0	0	0	11.1	0	11.1	11.1	5.6
Stage 4a Patients	5.6	5.6	16.7	0	33.3	0	11.1	0	11.1	0	16.7	0	5.6	11.1	5.6	55.6	0	5.6	5.6	5.6	0	5.6	0	5.6	0	16.7	5.6	0	0	11.1	2.6	33.3	5.6	0	0	27.8	11.1	0	0	5.6	5.6	0	5.6	0	0	5.6	0	11.1	5.6	0	5.6	5.6	22.2	0
Stage 4b Patients	0	0	5.3	5.3	15.8	5.3	5.3	0	10.5	5.3	0	5.3	0	5.3	0	36.8	5.3	0	0	5.3	0	0	5.3	10.5	5.3	21.1	10.5	15.8	10.5	0	0	21.1	0	0	5.3	5.3	5.3	10.5	5.3	0	0	0	0	5.3	0	0	5.3	0	0	0	5.3	0	5.3	5.3

Intervention	percentage of participants (Number)
	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5
High-Risk Hematologic Malignancies	0	3.2	61.3	19.4	16.1

Intervention	Percentage of participants (Number)
	The Cumulative Incidence of Relapse at five year p	Estimate±SE
High-Risk Hematologic Malignancies	30.0	8.6

Intervention	Percentage of participants (Number)
	Rate of Overall Grade III-IV Acute AVHD	Rate of limited grade Chronic GVHD
High-Risk Hematologic Malignancies	22.58	9.68

Intervention	Days (Median)
Single HST (CEM)	7
Tandem HST (CEM), Randomly Assigned	7
Not Assigned	7

Intervention	Percentage of patients (Number)
Single HST (CEM)	8.25
Tandem HST (CEM), Randomly Assigned	9.66
Not Assigned	7.78

Intervention	cells/mm^3 (Median)
	CD3	CD4	CD8
Single HST (CEM)	200	73	104
Tandem HST (CEM), Randomly Assigned	255.5	81	151

Intervention	Percentage of patients (Number)
Single HST (CEM)	13.11
Tandem HST (CEM), Randomly Assigned	12.50
Not Assigned	11.85

Intervention	L/h/m2 (Median)
Single HST (CEM)	28.1
Tandem HST (CEM), Randomly Assigned	28.1
Not Assigned	28.5

Intervention	Percentage of patients (Number)
Single HST (CEM)	83.98
Tandem HST (CEM), Randomly Assigned	84.09
Not Assigned	58.89